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ABSTRACT 
The aim of this study was to examine the effect of acute (Study 1) and chronic 
(Study 2) ingestion of a pre-workout supplement with (PWS+S) and without p-synephrine 
(PWS) on safety, metabolism, body composition and performance. In Study 1, 25 healthy, 
recreationally active participants ingested a dextrose flavored placebo (PLA); PWS 
containing 2 g arginine alphaketoglutarate, 3 g β-alanine, 270 mg caffeine, 2 g creatine 
nitrate, 15 mg L-Dopa, 300 mg N-acetyl L-tyrosine; or, the PWS with 20 mg p-synephrine, 
interspersed with a 7-d washout, in a randomized, crossover, counter-balanced manner. 
Participants were tested at time 0 (unsupplemented), and then 30-min and 90-min post 
ingestion. Data were analyzed by repeated measure MANOVA and reported as mean ± 
SD or mean change and 95% CI. Both treatment groups reported a greater sense of vigor 
and energy prior to exercise; PWS+S and PWS scored significantly higher on a Stroop 
Test. We observed significant differences in RER [PLA (0.89 ± 0.09) vs. PWS (0.92 ± 
0.06, p < 0.02) and PWS+S (0.85 ± 0.04, p = 0.006) and PWS vs. PWS+S (p < 0.001)]. In 
Study 2, 80 resistance trained male were randomized and ingested supplements; PLA, 
PWS, or PWS+S for 8-wk with resistance training. Testing occurred at baseline, wk 4, and 
wk 8. Data were analyzed by repeated measure MANOVA and reported as mean ± SD or 
mean change and 95% CI. We found significant increases in 1RM-Bench Press at wk 4 
for PWS and PWS+S, but not for PLA (5.45 kg, 95% CI, -0.82, 11.73). By wk 8 each 
group demonstrated significant 1RM-BP for PWS, PWS+S and PLA. A similar pattern 
was noted for 1RM-Leg Press at wk 4 for PWS and PWS+S, but not the PLA (36.50, 95% 
CI, -0.21, 73.2). By wk 8, all groups increased 1RM-LP. Our data suggest that a PWS 
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appears safe for acute ingestion and is efficacious regarding indices of cognitive function 
and exercise performance. We also found that ingesting a PWS during training appears 
safe, and the inclusion of p-synephrine is unnecessary to achieve the observed favorable 
effects to training adaptation. 
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NOMENCLATURE 
 
PWS  Pre-workout supplement 
PWS+S Pre-workout supplement with p-synephrine 
PLA  Placebo 
O2  Oxygen consumption or oxygen intake 
CO2  Carbon dioxide consumption or carbon dioxide intake 
E  Ventilatory equivalent 
RER  Respiratory exchange ratio 
REE  Resting energy expenditure 
SBP  Systolic blood pressure 
DBP  Diastolic blood pressure 
HR  Heart rate 
RHR  Resting heart rate 
DXA  Dual x-ray absorptiometry 
BMD  Bone mineral density 
LM  Lean mass 
FM  Fat mass 
FFM  Fat free mass 
RTP-VAS Readiness to perform visual analogue scale 
1RM  1 repetition maximum 
CBC  Complete blood count 
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RBC  Red blood cell 
WBC  White blood cell 
PLT  Platelet 
AST  Aspartate aminotransferase 
ALT  Alanine aminotransferase 
ALP  Alkaline phosphatase 
BUN  Blood urea nitrogen 
CRE  Creatinine 
CK  Creatine kinase 
LDH  Lactate dehydrogenase 
LDL-C Low density lipoprotein cholesterol 
HDL-C High density lipoprotein cholesterol 
ECG  Electrocardiogram 
BIA  Bioelectrical impedance analysis 
TBW  Total body water 
ECW  Extracellular water 
ICW  Intracellular water 
WAT  Wingate 30-sec anaerobic capacity test 
CHO  Carbohydrate 
FAT  Fat 
PRO  Protein 
ED  Energy drinks  
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CHAPTER I 
INTRODUCTION AND RATIONALE 
Background 
While dietary supplementation of various nutrients during training represents the 
most common means to enhance exercise performance [1-3], a number of nutritional 
strategies have been recently purported to affect acute performance by affecting physical, 
mental, and/or psychological performance [3-6]. For example, dietary supplements 
containing amino acids, caffeine, creatine, and vitamins have been reported to improve 
exercise capacity [3, 7, 8], muscle mass and strength [8], muscular endurance [9], and/or 
subjective feelings of focus and energy [10]. Additionally, the long term ingestion of pre-
workout supplements containing L-arginine, β-alanine, caffeine, and creatine have been 
reported to improve exercise capacity [11], body composition [12], muscle mass and 
strength [13], and/or subjective feelings of focus and energy [10]. 
L-arginine is a “semi-essential” amino acid [14] that plays an important role in the 
synthesis of metabolically active compounds, including other amino acids, muscle protein, 
and creatine [15]. L-arginine is the substrate of a family of enzymes named nitric oxide 
synthases (NOSs), and results in the release of nitric oxide (NO) and L-citrulline [16]. NO 
is critically important for hemodynamics by controlling coronary [17], pulmonary [18], 
adrenal [19], and systemic vascular tone [20]. Carnosine, a cytoplasmic dipeptide (β-
alanyl-L-histidine), is found in highest concentration in the skeletal muscle, whereby the 
chronic supplementation of β-alanine elevates muscle carnosine content by 40-80% [21] 
and attenuates the fall in blood pH during high-intensity exercise [22]. This ergogenic 
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mechanism may lead to an enhanced muscle buffering capacity by limiting the 
accumulation of hydrogen ions (H+) [23], and therefore it results in performance 
enhancement in high intensity anaerobic exercise [24] and delays fatigue [25]. Unlike the 
hemodynamic and hematologic change observed with L-arginine and β-alanine, caffeine 
is a central nervous system (CNS) stimulant, due to the binding of caffeine to 
benzodiazepine receptors [26]. Caffeine has demonstrated multiple beneficial effects for 
anaerobic power [27], high intensity exercise [28], and endurance performance [29]. 
Creatine is a naturally occurring compound [30] that is a member of the guanidine 
phosphagen family [31], and dietary nitrate is abundant in green leafy vegetables and 
beetroot [32]. 
The interest in pre-exercise ergogenic supplements following the ban of ephedra 
by the Food and Drug Administration (FDA) in 2004 has given rise to a number of pre-
workout supplement formulae combining various ingredients in an effort to enhance 
exercise and cognitive performance [33]. On such ingredient considered to be a metabolic 
stimulant and appetite suppressant is Citrus aurantium [34]. Historically, the Citrus 
aurantium has been mainly used for a variety for clinical applications, including 
indigestion, diarrhea and dysentery, constipation, and as an expectorant in traditional 
Asian medicine [35]. p-synephrine is an analog of ephedra found in the peel of Citrus 
aurantium or its extract [36] and has been used in weight loss dietary supplements due to 
its thermogenic effects [37]. In a review of the safety and efficacy characteristics of p-
synephrine, Haaz et al. [38] reported the p-synephrine alkaloid potentially increased 
energy expenditure and decreased food intake, as well as improving gastric motility and 
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appears to be safe with no serious adverse effects being directly attributable the compound 
itself [39]. Theoretically, adding p-synephrine to PWS formulations may therefore 
promote thermogenesis, increase perceptions of readiness to perform and/or cognitive 
performance, and possibly affect exercise capacity.   
Statement of the Problem 
 Is a multi-ingredient pre-workout dietary supplement with p-synephrine (PWS+S) 
safe, more efficacious to enhance performance than placebo (PLA) or PWS only (PWS) 
during acute and chronic ingestion? 
Purpose of the Study 
The primary aim of this study is to perform a two-phase series of clinical trials 
examining the (1) acute and (2) chronic response to a PWS formulated with (PWS+S) and 
without p-synephrine (PWS). The secondary aim of this study is to determine whether the 
form with p-synephrine is safe. The tertiary aim of this study is to examine which form of 
PWS is more efficacious to improve cognitive and exercise performance. 
General Study Overview 
 There were two experiments to perform the study. For Study 1, 25 healthy and 
recreationally active volunteers were recruited. The volunteers signed a study consent 
form, were underwent medical examination and familiarized to the study protocol. The 
volunteer who did not consent or was not medically cleared were withdrawn. At Day 1, 
the volunteers were randomized to one of double-labeled supplement groups; PLA, PWS, 
or PWS+S, and then they were provided with alternate supplement in counter-balanced 
manner after 7-day washout period. For Study 2, 80 resistance trained male volunteers 
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were recruited. In same manner of Study 1, the volunteers participated in the study. After 
all cleared, the eligible volunteers were asked to record 4-day food-log and invited to the 
baseline testing session (Day 1). After baseline testing, the volunteers were randomized to 
one of supplement groups, and then followed 8 week supplement and training protocol. 
The volunteers were asked to check-in the Exercise and Sport Nutrition Lab at Texas 
A&M University to perform a series of testing the same as baseline testing at week 4 and 
week 8. During Study 2, the volunteers were instructed to take 12 grams of supplement 
15-30 minutes prior to exercise and maintain their current diet throughout the study. 
Hypotheses 
 The central hypotheses are: 
Study 1 
H01: There will be significant differences of O2, CO2, and RER among groups 
for 30 minutes following supplementation. 
H02: There will be significant differences of cognitive function with Stroop Word-
Color test among groups prior to, during, and post-supplementation. 
H03: There will be significant differences of readiness to perform among groups 
prior to, during, and post-supplementation. 
H04: There will be significant differences of upper body strength with bench press 
test among groups after supplementation. 
H05: There will be significant differences of lower body strength with leg press test 
among groups after supplementation. 
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H06: There will be significant differences of anaerobic capacity with WAT among 
groups after supplementation. 
H07: There will be no significant differences of resting heart rate and blood pressure 
among groups prior to, during, and post-supplementation. 
H08: There will be no significant differences of blood metabolic markers; total 
cholesterol, HDL-C, LDL-C, and glucose, among groups prior to and 2-hr post-
supplementation. 
H09: There will be no significant differences of muscle enzymes; LDH and CK, 
among groups prior to and 2-hr post-supplementation. 
H010: There will be no significant differences of kidney enzymes; CRE and BUN, 
among groups prior to and 2-hr post-supplementation. 
H011: There will be no significant differences of liver enzymes; ALP, ALT, and AST, 
among groups prior to and 2-hr post-supplementation. 
Study 2 
H012: There will be no significant differences of training volume of upper and lower 
body among groups over 8 weeks following supplementation. 
H013: There will be no significant differences of consumption of macronutrient; 
CHO, FAT, and PRO, among groups over 8 weeks following supplementation. 
H014: There will be significant differences of fat mass with DXA body scan among 
groups over 8 weeks following supplementation. 
H015: There will be significant differences of cognitive function with Stroop Word-
Color test among groups over 8 weeks following supplementation. 
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H016: There will be significant differences of readiness to perform among groups 
over 8 weeks following supplementation. 
H017: There will be significant differences of upper body strength with bench press 
test among groups over 8 weeks following supplementation. 
H018: There will be significant differences of lower body strength with leg press test 
among groups over 8 weeks following supplementation. 
H019: There will be significant differences of anaerobic capacity with WAT among 
groups over 8 weeks following supplementation. 
H020: There will be no significant differences of blood metabolic markers; total 
cholesterol, HDL-C, LDL-C, and glucose, among groups over 8 weeks following 
supplementation. 
H021: There will be no significant differences of muscle enzymes; LDH and CK, 
among groups over 8 weeks following supplementation. 
H022: There will be no significant differences of kidney enzymes; CRE and BUN, 
among groups over 8 weeks following supplementation. 
H023: There will be no significant differences of liver enzymes; ALP, ALT, and AST, 
among groups over 8 weeks following supplementation. 
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Delimitations 
Study 1 
1. The volunteers were asked to not exercise for 48 hours nor eat or drink calorie
containing foods or drinks 10-12 hours before each testing session. 
2. The volunteers were instructed to refrain from ingesting caffeine and over the
counter medication with known stimulant use for 48 hours. 
3. The volunteers were scanned to measure the body composition with DXA.
4. The volunteers were asked to donate blood after 12-h fasting on testing day.
5. The volunteers were asked to perform their maximal ability with verbal
encouragement on all exercise and testing measures. 
6. There were not any performance tests as part of the study protocol.
7. The volunteers were limited to healthy and recreationally active individuals
between the ages of 18 to 40. 
8. The volunteers were asked to take a break no more than 5 minutes during testing
session. 
Study 2 
9. The volunteers were asked to not exercise for 48 hours nor eat or drink calorie
containing foods or drinks 10-12 hours before each testing session. 
10. The volunteers were instructed to refrain from ingesting caffeine and over the
counter medication with known stimulant use for 48 hours. 
11. The volunteers were scanned to measure the body composition with DXA.
12. The volunteers were asked to donate blood after 12-h fasting on testing day.
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13. The volunteers were asked to perform their maximal ability with verbal
encouragement on all exercise and testing measures. 
14. The volunteers were advised to maintain a consistent workout regimen
throughout the study. 
15. The volunteers were limited to healthy and resistance trained (6-month history
of resistance training) male between the ages of 18 to 40. 
16. The volunteers were advised to complete a 4-day dietary record (3 weekdays and
1 weekend) a week before baseline testing and 1st day of supplementation, and
then a week before the testing day at week 4 and week 8. 
17. The volunteers were advised to complete an 8-week resistance training record
(2-day upper body and 2-day lower body) throughout the study. 
18. The volunteers were instructed to intake the one packet (12 gram of supplement)
15-30 minutes before exercise on training day, and the one packet after breakfast 
on non-training day, and then were asked to take the empty packet back. 
19. The volunteers were refrained from drink other than water during testing session
and then provided glucose-electrolyte sport drinks after completing all testing. 
20. The volunteers were asked to donate muscle sample from the vastus lateralis at
pre- and post-supplementation (week 8). 
21. The volunteers were instructed to report any side-effects in a weekly
questionnaire. 
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Limitations 
1. The volunteers were individuals from the Texas A&M University community, 
Bryan/College Station area, and surrounding fitness facilities that respond to 
recruitment fliers and emails; therefore, the selection process does not truly 
random. 
2. While all effort was made to conduct testing sessions at the same approximate 
time to account for diurnal variations, there might be some variations in testing 
times and dietary intake. 
3. While the volunteers were required to maintain a consistent training program 
with supplementation and keep recording daily training-log, there might be some 
variations in the volume and intensity of individual’s workout. 
4. While the volunteers were encouraged to make the best effort to perform exercise 
testing, their intrinsic motivations and effort during the exercise bout and 
subsequent performance testing might not be maximized at each testing session. 
5. While the volunteers were instructed to follow the supplementation protocol, 
there might be some variations in an actual individual’s regimen. 
6. While all experiment equipment was calibrated according to manufacturer 
guidelines and all samples were run under the same condition, there might be 
some innate limitations of the laboratory equipment that was used for data 
collection and analysis. 
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7. While the volunteers were interviewed and recruited by confirmed
inclusion/exclusion criteria, there were innate limitations and variability in 
selection of volunteers. 
Assumptions 
1. The volunteers followed the overall study protocol and guideline that was
explained and consented during familiarization session. 
2. The volunteers adhered to 48-hour non-exercise and 12-hour fasting prior to each
testing session. 
3. The volunteers adhered to the 8-week supplementation protocol that would be
explained and consented. 
4. The volunteers recorded their 4-day diet-log and 4-day training-log, accurately
and honestly. 
5. The volunteers answered the entrance questionnaires and side-effect weekly
report in a regular basis, accurately and honestly. 
6. The trained research staff calibrated and ran all laboratory equipment to maintain
consistent. 
7. The study coordinator randomized the volunteers and allocated to each
supplement group evenly. 
8. The volunteers and research staff remained blinded to the assigned supplement
throughout the study. 
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CHAPTER II 
REVIEW OF LITERATURE* 
Pre-Workout Supplement 
While carbohydrate and/or protein supplements were a majority of dietary 
supplements for performance enhancement in past years [1, 40], a variety of dietary 
strategies were developed to enhance physical, mental, and even psychological 
performance in recent decade [4-6, 41-47]. Besides, in recent studies, it was reported 
energy drinks had similar effects to workout dietary supplements. One of the findings from 
these literatures is to provide appropriate dietary supplements as an ergogenic aid prior to 
exercise. Additionally, with resistance training, dietary supplements containing amino 
acids, caffeine, creatine, and vitamin have been reported to improve exercise capacity [11, 
48-52], body composition [12, 53], muscle mass and strength [8, 13, 54, 55], muscular 
endurance [56, 57], and/or subjective feelings of focus and energy [10, 58]. In Asia, many 
herbal supplements from vegetable and fruit also have been widely used as ergogenic aids, 
natural medication, or weight loss treatments. Among them, beetroot as a source of dietary 
nitrate are used to enhance oxygen uptake [59, 60], elevate metabolic rate [61], and 
improve exercise performance [62-66]. Velvet bean, Mucuna pruriens, extract is an 
established herbal drug used for the management of male infertility, nervous disorders, 
and also as an aphrodisiac [67]. In addition, bitter orange, Citrus aurantium, is used in 
herbal medicine as a stimulant and appetite suppressant [34], and it was developed for 
weight management supplement. 
* Creatine section in this chapter is reprinted with permission from Kreider RB and YP Jung. Creatine
Supplementation in Exercise, Sport, and Medicine. Journal of Exercise Nutrition and Biochemistry. 15(2): 
53-69, 2011. DOI: 10.5717/jenb.2011.15.1.053.  
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In addition to PWS, energy drinks (ED) have been used as an ergogenic aid among 
active population. A main ingredient of ED is caffeine, and typically caffeinated energy 
drinks contain from 25 to 250 mg of caffeine in various forms [68]. Shearer et al. [68] 
reported caffeinated ED increased 1.64 minute (3.6%) of performance time by comparing 
24 studies. Administration of 1.3 mg/kg of caffeine resulted in an increased in the running 
distance in team sports such as rugby or soccer [69], in particular. In International Society 
of Sports Nutrition (ISSN) position stand regarding energy drink [33], it was reported that 
consuming in low-to-moderate dosages (3-6 mg/kg) is effective for enhancing sport 
performance in trained athletes, while there was no further enhancement in performance 
with higher dosages (>9 mg/kg). Prior to muscle endurance exercise, ingestion of ED (2 
mg/kg caffeine) increased approximately 6% more repetitions of failure to 3 sets 70% 
1RM [70]. Other than caffeine, guarana, natural source of caffeine, citrulline malates, and 
synephrine were suggested to affect performance, as well. Further these stimulants mainly 
have benefits to reaction time, concentration, alertness, and subjective feelings of energy 
which are important in competitive activity such as hitting a baseball or returning a serve 
in tennis [33]. 
Arginine α-ketoglutarate (AAKG) 
L-arginine is a semi-essential amino acid [14] that plays an important role in the 
synthesis of metabolically active compounds, including other amino acids, muscle protein, 
and creatine [15, 30]. L-arginine is a natural constituent of dietary proteins and classified 
as a glucogenic amino acid because it can be metabolized into α-ketoglutarate (AKG) 
entering the citric acid cycle [14]. It was proposed that tricarboxylic acid cycle 
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intermediates (TCAIs) intake might increase physical performance due to the fact that 
theoretically TCAIs are limiting factors of TCA cycle, and its supplementation will help 
to lift these limitation [71]. In addition, administration of AKG with calcium carbonate 
was reported to effectively improve amino acid metabolism in hemodialysis patients as it 
decreases hyperphosphatemia [72]. L-arginine as the substrate of a family of enzymes 
named nitric oxide synthases (NOSs), results in the release of nitric oxide (NO) and L-
citrulline [16]. Nitric oxide produced by this pathway is critically important for 
hemodynamics by controlling coronary [17, 73, 74], pulmonary [18], adrenal [19, 75], and 
systemic vascular tone [20, 76]. 
For the theoretical background, L-arginine has been introduced first as a “Cardio-
enhancing Supplement” by Fried et al. in 1999 [77]. Maxwell et al. [78] showed 
administration of L-arginine restored exercise-induced endothelium-derived nitric oxide 
synthesis and normalized aerobic capacity in hypercholesterolemic mice. In clinical trials, 
Nagaya et al. [79] suggested L-arginine supplementation might have beneficial effects on 
hemodynamics and exercise capacity in patients with precapillary pulmonary 
hypertension. Further, Campbell et al. [14] observed an acute ingestion of arginine-AKG 
(4 gram) showed significant difference of plasma arginine levels in blood, and 12 grams 
supplementation (3 times of 4 g/day) with resistance training for 8 weeks had positive 
effects of 1 RM bench press and Wingate peak power performance in trained adult men. 
Chen et al. [80] showed an ergogenic benefit of arginine and antioxidant-containing 
supplement on anaerobic threshold in elderly cyclists, and similarly Yavuz et al. [81] 
showed arginine alone supplement group (1.5 gram per 10 kg) for elite male wrestlers had 
14 
 
longer time to exhaustion of cycle ergometer compared with placebo group. Among the 
studies regarding multi ingredients dietary supplements, Camic et al. [82] found arginine-
based supplement (3 gram of arginine) to healthy college-aged men for 4 weeks increased 
gas exchange threshold and power output, and Zak et al. [15] also supported arginine-
based supplement (3 gram of arginine) might be used to delay the onset of neuromuscular 
fatigue and improve the ventilatory threshold in untrained individuals.    
β-alanine 
Carnosine, a cytoplasmic dipeptide (β-alanyl-L-histidine), is found in highest 
concentration in the skeletal muscle (5-10 mM) and other excitable tissues such as nervous 
tissue [83]. Due to its acts as a physicochemical buffer in myocytes, it is present mostly 
higher concentrations in glycolytic than in oxidative muscle fibers [83]. Derave et al. [83] 
concluded increased muscle carnosine levels attenuated fatigue in repeated bouts of 
exhaustive dynamic contraction in trained sprinters, and Baguet et al. [22] also suggested 
that exercise performance improved by high carnosine was because of increase in the non-
bicarbonate muscle buffering capacity, increase in the sensitivity of calcium release 
channels and/or the calcium sensitivity of the contractile apparatus, decrease in the 
reactive oxygen species (ROS) accumulation, and vasodilation. 
Several studies reported the chronic supplementation for 4 week to 8 week of β-
alanine elevates muscle carnosine content by 40-80% [21, 83, 84]. del Favero et al. [85] 
reported 3.2 gram of β-alanine supplement for 12 week was effective in increasing 85.4% 
of the muscle carnosine content of the gastrocnemius muscle in healthy elderly subjects. 
For 4 weeks, 6.4 g/day of β-alanine supplementation showed also a significant increase in 
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the muscle carnosine content of all fiber phentotype, with no significant difference 
between types [86]. Harris et al. [87] found the supplementation of 3.2 g/day and 6.4 g/day 
of β-alanine, and total 364 gram of L-carnosine for 4 weeks resulted in significant increases 
in muscle carnosine estimated at 42.1%, 64.2% and 65.8%, respectively. Danaher et al. 
[88] reported a coingestion of β-alanine and sodium bicarbonate (NaHCO3) elevated 
buffering potential by increasing muscle carnosine and blood bicarbonate levels, 
respectively. 
Aside from a change of muscle carnosine level, β-alanine supplementation 
attenuates the fall in blood pH during high-intensity exercise [22], and this ergogenic 
mechanism may lead to an enhanced muscle buffering capacity by limiting the 
accumulation of hydrogen ions (H+) [23]. In healthy elderly study of del Favero et al. [85], 
it was observed that 36.5% of time-to-exhaustion in the constant-load submaximal test. 
Like the elderly, college wrestlers and football players ingesting 4 gram of β-alanine for 
8 weeks also showed improved performance, decrease in 300 shuttle time by 1.1 seconds 
and increase in 90° flexed-arm hang [89]. In football players with 4.5 gram of β-alanine 
supplement for 30 days during training camp, a trend was observed for a lower fatigue 
rate for supplement group compared with placebo group during the 60 second Wingate 
anaerobic power test [25]. High intensity interval training (HIIT) with β-alanine 
supplement (1.5g/day) for six weeks led to improve maximal oxygen consumption rate 
(VO2peak), cycle ergometer workload at the ventilatory threshold (VTw), and even body 
composition; decrease in fat mass and increase in fat free mass [24]. Therefore β-alanine 
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supplement results in performance enhancement in high intensity anaerobic exercise [24, 
85, 89] and delays fatigue [25]. 
Caffeine 
Unlike the hemodynamic change observed with L-arginine and β-alanine, caffeine 
(C8H10N4O2) was considered to be a central nervous system (CNS) stimulant. Due to the 
characteristics of high lipid solubility, caffeine readily crosses the blood-brain barrier both 
by diffusion and by a saturable transport system [90]. In this paper, Nehlig et al. [90] also 
proposed three main mechanisms of action of caffeine, intracellular mobilization of 
calcium, inhibition of phosphodiesterases, and antagonism at the level of adenosine 
receptors. With these mechanisms, Nehlig and Debry suggested caffeine increases 
production of plasma catecholamines that allow the body to adapt to the stress increased 
by physical activities and increases muscle contractility that improve time to exhaustion, 
physical performance, and endurance during prolonged activity of submaximal intensity 
[91]. 
Due to these facts, caffeine is one of the most widely used ergogenic aids, and 
various forms of caffeine supplements have become more available over the commercial 
market in recent years [92-100]. Furthermore, such ergogenic effects of caffeine as 
metabolic, hormonal, physiologic and cognitive function have been shown in various 
ranges of studies [97, 101-107]. Among these studies, Ahrens et al. [101] found 6 mg/kg 
of caffeine ingestion improved oxygen uptake (VO2), rate of energy expenditure, 
percentage of maximal oxygen uptake (%VO2) compared with placebo in women. 
Additionally, Anselme et al. [107] found caffeine increased blood lactate concentration. 
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Further, Birnbaum et al. [102] revealed 7 mg/kg of caffeine prior to submaximal running 
provided a modest ergogenic effect via improved respiratory efficiency and a 
psychological lift of cross-country runners. While 5 mg/kg of caffeine did not showed a 
significant change of maximal anaerobic capacity and anaerobic power, it induced 
significant increases in both catecholamine and blood lactate [27]. The findings of 
Hogervorst et al. [97] supported caffeine improved cognitive performance by showing 
better cognitive performance of caffeine group than other groups. 
In the studies regarding caffeine supplement and performance, caffeine has 
demonstrated multiple beneficial effects for anaerobic power [27, 108], high intensity 
exercise [28], aerobic endurance [29, 96, 98, 109], strength [93], team sport performance 
[110, 111], and cognitive performance [97, 104, 105]. Eudy et al. [112] reported an amount 
of 100-500 mg provided beneficial effects such as increased alertness, stimulation, and 
euphoric effects. In another recent review, Glade [113] concluded the consumption of 
moderate amounts of caffeine had beneficial effects of mental energy, cognitive function, 
and neuromuscular coordination as well as physical performance and endurance 
enhancement. Koppelstaetter et al. [114] showed 100mg of caffeine intake modulated the 
functional magnetic resonance imaging (fMRI) signal during working memory processes 
in brain regions that have been associated with attentional and executive functions. 
Interestingly, a study of caffeine ingestion effect on mood, concentration, and arousal state 
during a university lecture revealed 100 mg of caffeinated supplement leads to enhanced 
perceptual feeling of behavior and mood state during a 75-min lecture [115]. In motor 
coordination study for Navy SEALs [116], 62 male trainees with taking 200 or 300 mg of 
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caffeine were enabled to sight the target and pull the trigger faster without compromising 
shooting accuracy during periods of sleep deprivation combined with other stressors.   
Creatine 
Creatine is a naturally occurring compound that is a member of the guanidine 
phosphagen family [31]. Creatine is primarily found in the skeletal muscle (~95 %) with 
small amounts found in the brain and testes (~5 %). About two thirds of creatine in the 
muscle is stored as phosphocreatine (PCr) while the remaining amount of creatine is stored 
as free creatine. The total creatine pool (PCr + free creatine) in the muscle averages about 
120 grams for a 70 kg individual [117]. However, the upper limit of creatine storage 
appears to be about 160 grams of creatine in most individuals [117-119]. About 1-2 % of 
the creatine in the muscle is degraded into creatinine and excreted in the urine per day. 
Therefore, the body needs to replenish about 1-3 grams of creatine per day to maintain 
creatine stores. About half of the daily need for creatine is obtained from the diet. For 
example, there is about 1-2 grams of creatine in a pound of uncooked beef and salmon 
[120]. The remaining amount of creatine is synthesized from arginine, glycine, and 
methionine [121]. Vegetarians have been reported to have muscle creatine stores in the 
90-110 gram range [122]. Additionally, some people have been found to have creatine 
synthesis deficiencies and therefore must depend on dietary creatine intake in order to 
maintain normal muscle and brain concentrations of creatine and phosphocreatine [123]. 
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The primary metabolic role of creatine (Cr) is to combine with a phosphoryl group 
(Pi) to form PCr through the enzymatic reaction of creatine kinase (CK). Wallimann and 
colleagues [124-127] suggested that the pleiotropic effects of Cr are mostly related to the 
functions of CK and PCr (i.e., CK/PCr system). As adenosine triphosphate (ATP) is 
degraded into adenosine diphosphate (ADP) and Pi to provide free energy for metabolic 
activity, the free energy released from the hydrolysis of PCr into Cr + Pi can be used as a 
buffer to resynthesize ATP. This helps maintain ATP availability particularly during 
maximal effort anaerobic sprint-type exercise. The CK/PCr system also plays an important 
role in shuttling intracellular energy from the mitochondria into the cytosol. The CK/PCr 
energy shuttle connects sites of ATP production (glycolysis and mitochondrial oxidative 
phosphorylation) with subcellular sites of ATP utilization (ATPases) [125]. In this regard, 
creatine enters the cytosol through a creatine transporter (CRT). In the cytosol, creatine 
and associated cytosolic and glycolytic CK isoforms help maintain glycolytic ATP levels, 
the cytosolic ATP/ADP ratio, and cytosolic ATP-consumption [125]. Additionally, 
creatine diffuses into the mitochondria and couples with ATP produced from oxidative 
phosphorylation and the adenine nucleotide translocator (ANT) via mitochondrial CK. 
ATP and PCr can then diffuse back into the cytosol and help buffer energy needs. This 
coupling also reduces formation of reactive oxygen species (ROS) and can therefore act 
as a direct and/or indirect anti-oxidant. The CK/PCr energy shuttle thereby connects sites 
of ATP production (glycolysis and mitochondrial oxidative phosphorylation) with 
subcellular sites of ATP utilization (ATPases) in order to fuel energy metabolism [125]. 
In this way, the CK/PCr system thereby serves as an important regulator of metabolism 
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which may help explain the ergogenic and potential health benefits of creatine 
supplementation [31, 124, 128]. 
Short-term creatine supplementation has been reported to improve maximal 
power/strength (5-15%), work performed during sets of maximal effort muscle 
contractions (5-15%), single-effort sprint performance (1-5%), and work performed 
during repetitive sprint performance (5-15%) [129]. Long-term creatine supplementation 
appears to enhance the quality of training generally leading to 5 to 15% greater gains in 
strength and performance [129]. Additionally, most studies indicate that creatine 
supplementation increases body mass by about 1 to 2 kg in the first week of loading [129]. 
Although the initial weight gain has been suggested to be related to fluid retention, subjects 
taking creatine typically gain about twice as much body mass and/or fat free mass during 
training than subjects taking a placebo (e.g., an extra 1-2 kg of muscle mass during 4 to 
12 week of training). No study has reported that creatine supplementation significantly 
impairs exercise capacity. 
Mucuna pruriens (Velvet Bean) Extract 
 Mucuna pruriens or Velvet bean is a tropical legume widespread throughout 
Africa and Asia, and it is widely naturalized and cultivated to use a rich source of 
macronutrient and microelements [130]. Mucuna pruriens has been used as a natural herb 
drug in the clinical treatment of the Parkinson’s disease by many countries in Asia. India 
having a long history of many herbal drugs officially recognizes an usage of herbal drugs 
is an alternative medicine for anti-diabetes, anti-aging, anti-cancer, as well as   anti-
parkinsonism [131]. Parkinson’s disease, a neurodegenerative disease, is defined by low 
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levels in the brain of the neurotransmitters dopamine [132]. Mucuna pruriens seeds are a 
good source of the non-protein amino acid L-3,4-dihydroxyphenylalanine (L-Dopa), a 
precursor of dopamine [130]. Due to its solubility, dopamine itself cannot cross blood 
brain barrier (BBB), formed by endothelial cells with the presence of tight junctions. Since 
dopamine itself is unstable, it should be formed within the brain by conversion of its 
precursor L-Dopa to transit through BBB [132]. 
In a double blind and randomized control study, it was found that Mucuna pruriens 
possessed advantages over conventional L-Dopa preparations in the long term 
management of Parkinson disease [133]. Daily feeding ad lib of three different dosages of 
2.5, 5.0, or 10.0 g/kg/day with rat chow to Sprague-Dawley rats had a significant effect 
on dopamine content in the cortex with no significant effect on levodopa, norepinephrine 
or dopamine, serotonin [134]. Suresh et al. [135] showed 60 days supplementation of 
Mucuna pruriens significantly reduced reactive oxygen species (ROS) and lipid 
peroxidation (LPO) production and significant increase in both enzymatic and non-
enzymatic antioxidant levels in aged rat sperm. Treatment of Mucuna pruriens to infertile 
men also significantly improved Serum T, luteinizing hormone (LH), dopamine, 
epinephrine, and norepinephrine levels and reduced levels of follicle stimulating hormone 
(FSH) and prolactin (PRL) [136]. In exercise-trained men, 2250 mg of a blend of 
Chlorophytum borivilianum root and Mucuna pruriens increased serum growth hormone 
(GH) over time at 60 minutes, 80 minutes, and 100 minutes compared to pre-ingestions 
[137]. 
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N-Acetyl-L-Tyrosine is a more soluble form of L-Tyrosine and is usually modified 
from normal tyrosine. In the same way of Mucuna pruriens extracts, L-Tyrosine is 
converted to L-Dopa, and the increase in L-Dopa, as a precursor of dopamine, boosts the 
synthesis of dopamine. The conversion mechanism of tyrosine to dopamine is well-
established. Acute administration of an amino acid mixture that selectively lacks both 
tyrosine and its precursor phenylalanine has been shown to be effective in decreasing 
availability of tyrosine to the brain through processes of increased protein synthesis and 
increased competition for transport across the BBB [138]. In this study, Harmer et al. [138] 
examined the effect of acute tyrosine depletion on dopamine function in healthy volunteers 
and found they were impaired at spatial recognition memory and spatial working memory 
following the tyrosine-free drink. 
Nitrate 
Unlike creatine high in animal protein source, dietary nitrate is abundant in green 
leafy vegetables and beetroot [32]. A diet high in NO3
- has been found to have a beneficial 
impact on several body function and sports performance as an ergogenic aid [65, 66, 139-
143]. In particular, the beetroot, an excellent source of NO3
-, has been used to improve 
blood pressure as an alternative of antihypertensive drugs [144]. The NO3
- can be reduced 
to NO2
- and in turn to NO. The NO is an important cellular signaling molecule involved 
in many physiological and pathological processes, and it affects to blood vessel as a 
powerful vasodilator with a short half-life of a few seconds in the blood. 
Recent evidences suggest that beetroot juice supplementation may positively 
impact the physiological response to exercise [61, 65, 145-147]. It has been reported that 
N-Acetyl L-Tyrosine (NALT) 
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beetroot juice can enhance NO production in the skeletal muscle, thereby increasing blood 
flow and improving muscle O2 delivery [63, 148]. These effects are not only for 
hypertension patients but also for sports athletes. The Australian Institute of Sport 
recommended that typical dose used in recent studies of sports and exercise performance 
be ~5-6 mmol or ~300 mg nitrate provided by a single serve of beetroot, consumed ~2-
2.5 hours pre-exercise. The ergogenic effects of beetroot juice supplementation have been 
tested in various sports, and in a 6 days supplement study for cyclists, in particular, 
beetroot juice group showed a significance of time-trial performance (BR: 953 ± 18 sec 
vs. PL: 965 ± 18 sec) and power output (BR: 294 ± 12 W vs. PL: 288 ± 12 W) compared 
with placebo group [66]. In randomized controlled trial study, acute ingestion of beetroot 
showed the incremental area under the curve (0-6 h after ingestion) for endothelium-
independent vasodilation was greater (p = 0.017) and lower for diastolic blood pressure (p 
= 0.032) [149]. 
While the safety of creatine monohydrate as a dietary supplement has been 
extensively studied in athletes [150-153], muscular dystrophy patient [154, 155], 
mitochondrial diseases [156], Parkinson disease [157, 158], fibromyalgia patients [159] 
and confirmed [160], creatine nitrate is a relatively new and novel form of creatine bound 
to a nitrate molecule [161]. Creatine nitrate has high water solubility compared with 
creatine monohydrate or buffered creatine. This form of creatine is currently being tested 
to see its worth as a nutritional supplement [162], particularly in PWS, and additional 
research is needed to assess the ergogenic value. 
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p-synephrine, structurally similar to epinephrine [163], is found in a peel of bitter 
orange (Citrus aurantium) or its extract [36]. As a safe alternative to ephedra, it is 
marketed and widely used in weight loss or weight management.  In a review for safety 
and efficacy of p-synephrine, Haaz et al. [38] reported synephrine alkaloid potentially 
increased energy expenditure and decreased food intake, as well as decreased gastric 
motility.  Stohs et al. [39] summarized in their review that the use of bitter orange extract 
and p-synephrine appears to be exceedingly safe with no serious adverse effects being 
directly attributable to these ingredients.  
In a study for thermic effect of food extracted from Citrus aurantium [164], Citrus 
aurantium increased energy metabolism in women and had no effect on blood pressure 
and pulse rate while epinephrine excretion was increased by 2.4-fold. A study of acute 
administration of p-synephrine with caffeine in young adults showed a dietary supplement 
with 13 mg of p-synephrine and 176 mg of caffeine lead not to increase cardiovascular 
stress and lead to increase in fat oxidation in certain population [165]. In a 28-d study in 
rats, Hansen et al. [166] found the increase in heart rate and blood pressure supplemented 
with caffeine, but no treatment effect on QT interval without caffeine. Additionally, Kaats 
et al. [167] found no adverse effects at a dose of up to 98 mg/d of p-synephrine for 60-d 
in a double-blind and placebo-controlled study in healthy adults. However, some case 
studies have reported p-synephrine to have adverse effects [168-170]; yet, no research has 
examined the interaction between dietary supplement ingredients in combination with p-
synephrine to resistance trained male during acute and chronic ingestion. 
Citrus aurantium (Bitter Orange) Extract 
25 
As previously mentioned in PWS and ED, dietary supplements prior to exercise 
mainly improve alertness and readiness to perform, and it consequentially leads to 
performance enhancements. Despite some adverse case reports, Citrus aurantium extract 
appear to be effective ergogenic supplement. In addition to lipolytic activity, p-synephrine 
stimulate glucose consumption by stimulating AMPK activity which thought to be 
important for mitochondrial adaptations to exercise training [171]. Also, ingestion of p-
synephrine alone showed greater increase in resting metabolic rate than placebo [172]. 
Because of these reasons, it would be considered to be a potential PWS. 
Summary 
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CHAPTER III 
METHODS 
Study 1: Acute Supplementation 
Study 1 was an acute phase study with participants ingesting each respective 
supplement one time in a randomized, double blind, crossover manner. Primary outcome 
variables were readiness to perform exercise.  Secondary and tertiary outcomes included 
the blood pressure, heart rate, resting energy expenditure (REE), hematological, strength, 
and anaerobic power response to supplementation. Each participant was randomly 
assigned to ingest the supplements described below in double blind and crossover manner.  
The experiment was repeated after a 7-d washout period observed between each testing 
session. Table 1 presents an overview of the Study 1. 
Each study was performed at the Exercise & Sport Nutrition Laboratory (ESNL) 
at Texas A&M University after obtaining ethical approval from the universities ethics 
committee. Herein we provide a concise overview of Study 1 testing procedures followed 
by a detailed accounting for all testing methodologies. 
Participants 
Apparently healthy and recreationally active men and women were recruited and 
participated in this study after obtaining ethical approval from the universities Internal 
Review Board. Inclusion criteria required that each participant have at least six months of 
resistance training experience immediately prior to entering the study inclusive of 
performing bench press and leg press or squat. Participants were excluded if they 
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Table 1. Study 1 Protocol Overview 
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presented with a history of treatment for metabolic disease, hypertension, thyroid disease, 
arrhythmias, and/or cardiovascular disease; and/or, were they are currently using any 
prescription medication. Further exclusion criteria also included an intolerance to caffeine 
and/or other natural stimulants; pregnant or lactating women; a history of smoking; and, 
excessive alcohol consumption (>12 drinks/wk).  Participants who met study entry criteria 
were invited to a familiarization session.  
Familiarization Session 
During familiarization, the details of the study were explained, informed consent 
was obtained, and medical history information was completed via a general clinical exam 
to determine eligibility to participate in the study. At this same session, participants were 
assessed for height and body mass and had dual energy X-ray absorptiometry (DXA) body 
composition (excluding cranium) determined. 
Following these assessments, participants performed a one repetition maximum 
(1RM) test on the bench press and leg press. All strength testing took place on an isotonic 
Olympic bench press and hip/leg sled (Nebula Fitness, Versailles, OH) using standard 
procedures [173]. Maximal strength was determined following a standard warm-up 
consisting of 10 repetitions using 50% of their estimated 1RM, 5 repetitions using 70% of 
their estimated 1RM, and 1 repetition using 90% of their estimated 1RM. Participants 
continued increasing weight until their 1RM’s were determined. Participants were 
encouraged to reach 1RM during the familiarization trials. Previous research in our lab on 
resistance-trained participants has yielded a low day-to-day mean coefficients of variation 
and high reliability for the bench press and leg press (1.1%, intra-class, r = 0.99). After 
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then, participants practiced the Wingate anaerobic capacity testing procedures. Those who 
were cleared were scheduled to begin baseline testing. 
Pre- and Post-Supplementation Testing Procedures 
Prior to testing, we instructed participants to refrain from exercise, caffeine, and 
supplements and/or medications containing stimulants for 48-hr prior to testing. 
Participants presented to the lab after a 12-hr fast and donated ~ 20 ml of blood via 
venipuncture. Following blood sampling, we administered a series of tests to assess: 
cognitive function (Stroop Test), Readiness to Perform Visual Analogue Scale (RTP-
VAS), resting blood pressure (BP), resting heart rate (HR), and resting energy expenditure 
(REE) for 10 minutes. 
After 10-min pre-supplementation procedures, each participant was randomized in 
counterbalanced and double-blinded manner to ingest the respective supplements. 
Participants were monitored BP, HR and REE every 10-min for 30-min post-
supplementation. After rest testing, participants performed a 5-min warm up followed by 
3 sets of 10 repetitions at 70% of 1RM on the bench press and leg press interspersed by 
two minutes of rest between sets and 5-min recovery between each exercise testing 
modality. During the third set, we asked participants to complete as many repetitions as 
possible. Following a 5-min recovery, participants performed a standard Wingate test to 
assess anaerobic capacity peak power (PP), mean power (MP) and total work (TW) on a 
computerized cycle ergometer. Participants then performed a final series of cognitive 
function and readiness to perform testing and donated a third blood sample. Figure 1 
shows the timeline of testing procedures. The experiment was repeated using the alternate 
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supplement administered in a counterbalanced manner two additional times following 7-
day washout after each additional testing session.  
 
 
Figure 1. Study 1 Timeline of Measurement Procedures 
 
Supplements 
Treatments consisted of a (1) flavored placebo (PLA), (2) a PWS containing 
arginine alpha-ketoglutarate (2 g), β-alanine (3 g), caffeine (270 mg), creatine nitrate (2 
g), N-Acetyl-L-Tyrosine (300 mg), Mucuna pruriens extract standardized for 15% L-Dopa 
(15 mg), Vitamin C as Ascorbic Acid (500 mg), niacin (60 mg), folate as folic acid (50 
mg), and Vitamin B12 as Methylcobalamin (70 mg) (Nutrabolt, Bryan, TX); or, (3) the 
PWS with Citrus aurantium extract standardized for 30% synephrine (20 mg) (PWS+S) 
(Nutratech Inc., Caldwell, NJ). Figure 2 and Figure 3 present the supplement facts of PWS 
and the product specification of synephrine, respectively.  
Supplements were prepared in 12 g of pink powder in A, B, and C coded single 
foil packets and labeled for double blind administration (A: PWS+S, B: PWS, and C: PLA). 
Supplements were provided by the supporting, and were counted and pre-packaged by an 
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individual outside of the research team. The ingredients of the packets were independently 
verified by VMI Nutrition (Salt Lake, UT). 
 
  
Figure 2. Supplement Facts of PWS  
 
Testing Methodologies 
Anthropometry: At familiarization session of Study 1, height and weight, and 
body composition were determined. Body mass and height were determined via a 
calibrated scale (Cardinal Detecto Scale Model 8430, Webb City, MO) and body 
composition was determine using a Dual Energy X-Ray Absorptiometer (DXA) excluding  
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Figure 3. Product Specification of Synephrine 
 
cranium (Discovery W, Hologic Inc., Waltham, MA). Previous studies indicate DXA to be 
an accurate and reliable means to assess changes in body composition [174]. For 
determination of body composition, participants removed all metal objects that are known 
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to interfere with measurement. Participants were then positioned in the supine position 
based on manufacture’s guideline by a trained technician. DXA measurement was then 
performed; taking approximately 6-8 minutes. Analysis was immediately performed by a 
trained technician to determine body composition. Test/retest reliability studies performed 
on male athletes with DXA yielded mean deviation for total bone mineral content and total 
fat-free-soft tissue mass of 0.31-0.45%, with a mean intra-class correlations of 0.985 [174]. 
Blood Chemistry: During testing, total three blood samples were collected at pre-
supplement, 60min post-supplement, and 120min post-supplement. All blood samples 
were analyzed for standard blood chemistries inclusive of alkaline phosphatase (ALP), 
aspartate transaminase (AST), alanine transaminase (ALT), creatinine, blood urea 
nitrogen (BUN), creatine kinase (CK), lactate dehydrogenase (LDH), glucose, and blood 
lipids (total cholesterol, high density lipoprotein [HDL], low density lipoprotein [LDL], 
triglycerides [TG]) using a Cobas® c111 (Roche Diagnostics, Basel, Switzerland). The 
Cobas® automated clinical chemistry analyzer was calibrated according to manufacturer 
guidelines. This analyzer has been known to be highly valid and reliable in previously 
published reports [175]. The internal quality control for the Cobas® c111 was performed 
using two levels of control fluids purchased from manufacturer to calibrate acceptable SD 
and coefficients of variation values for all aforementioned assays. Samples were re-run if 
the observed values were outside control values and/or clinical norms according to 
standard procedures. We also assessed a complete blood count with platelet differential 
on whole blood (hemoglobin, hematocrit, red blood cell counts, MCV, MCH, MCHC, 
RDW, white blood cell counts, lymphocytes, granulocytes, and mid-range absolute count 
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(MID) using a Abbott Cell Dyn 1800 (Abbott Laboratories, Abbott Park, IL, USA) 
automated hematology analyzer. The internal quality control for Abbott Cell Dyn 1800 
was performed using three levels of control fluids purchased from manufacturer to 
calibrate acceptable Cv values for all whole blood cell parameters (± 6.27%). 
Blood Pressure and Heart Rate Assessment: Resting blood pressure (BP) and 
resting heart rate (HR) were determined by palpation of the radial artery using standard 
procedures and aneroid sphygmomanometer. Blood pressure was also assessed using 
standard auscultatory procedures [176].  
Cognitive Function (Stroop Word-Color Test): During testing, cognitive function 
was tested with Stroop Word-Color test standardized by Golden [177]. The test consists 
of three pages (Fig. 4). Each page has 100 items, presented in 5 columns of 20 items. Items 
on the Page 1 (Word) are the color words RED, GREEN, and BLUE in black ink. On the 
Page 2 (Color) the items are XXX’s colored in red, green, or blue ink. Items on the Page 
3 (Word-Color) are the words RED, GREEN, and BLUE printed in red, green, or blue ink 
with the limitation that word and ink could not match. Participants read loudly each page 
(Word, Color, and Word-Color page in order) for 45 second as fast as they can. 
Readiness to Perform Visual Analogue Scale: With same as cognitive function, 
Readiness to Perform was tested three times and measured by visual analogue scale (VAS) 
with five subjective feeling (strongly disagree to strongly agree) on 20 cm dotted bar (Fig. 
5). The VAS has six questions; (1) “I slept well last night”, (2) “I am looking forward to 
today’s workout”, (3) “I am optimistic about my future performance”, (4) “I feel vigorous 
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Figure 4. Stroop Word-Color Test Sheets 
Page 1 Page 2 Page 3 
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Figure 5. Readiness to Perform Visual Analogue Scale 
 
and energetic”, (5) “My appetite is great”, (6) “I have little muscle soreness”. Participants 
circled the number or dotted between numbers that best indicated how they currently felt. 
Strength Testing with 1RM: With 1RM determined at familiarization, participants 
performed 3 sets of bench and leg press test. At the first and second set, participants were 
asked to lift 10 repetitions at 70% of 1RM on the bench press and leg press interspersed 
by two minutes of rest between sets and 5-minute recovery between each exercise testing 
modality. During the third set, we asked participants to complete as many repetitions as 
possible they can. 
Wingate Anaerobic Capacity Testing: Wingate testing was assessed using a Lode 
Excalibur Sport Ergometer (Lode BV, Groningen, The Netherlands) and work rate was set 
at of 7.5 J/kg/rev. Participants were asked to pedal as fast as possible prior to application 
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of the workload and sprint at an all-out maximal capacity for 30-sec Wingate test. Test-
to-test variability in performing repeated Wingate anaerobic capacity tests in our lab have 
yielded correlation coefficients of r = 0.98±15% for mean power. 
Study 2: Chronic Supplementation 
Study 2 was an 8-wk study using different participants receiving supplements in a 
randomized, double blind manner. Primary outcome variables were exercise performance; 
upper and lower body strength, and anaerobic power. Secondary and tertiary outcomes 
included the readiness to perform exercise, blood pressure, heart rate, and hematological 
response to supplementation. Table 2 presents an overview of the Study 2. 
Each study was performed at the Exercise & Sport Nutrition Laboratory (ESNL) 
at Texas A&M University after obtaining ethical approval from the universities ethics 
committee. Herein we provide a concise overview of Study 2 testing procedures followed 
by a detailed accounting for all testing methodologies. 
Participants 
We recruited male participants and administered the study as a randomized, double 
blind, placebo-controlled trial lasting eight weeks. Inclusion criteria required that each 
participant have at least six months of resistance training immediately prior to entering the 
study inclusive of performing bench press and leg press or squat. Participants were 
excluded if they presented with a history of treatment for metabolic disease, hypertension, 
thyroid disease, arrhythmias, and/or cardiovascular disease; and/or were they are currently 
using any prescription medication. Further exclusion criteria also included an intolerance 
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to caffeine and/or other natural stimulants; a history of smoking; excessive alcohol 
consumption (>12 drinks/wk).  
Familiarization Session  
Participants who met study entry criteria were invited to a familiarization session 
where the details of the study were explained, signed, informed consent was obtained 
medical history information was completed via a general clinical exam that included an 
assessment of fasting blood (i.e., to rule out diabetes) to determine eligibility to participate 
in the study. Those who were cleared were then scheduled to begin baseline testing.  
Baseline Testing 
Before baseline testing, we instructed participants to refrain from exercise, caffeine, 
and supplements/medications containing stimulants for 48-h. prior to testing. Participants 
presented to the lab after a 12-h fast and were required to provide 4-d food-log recorded 
their consumption of food a week before testing session. Once checked in, participants 
donated ~ 20 ml of blood via venipuncture, and we administered a series of tests to assess 
body composition: body weight, body water (BIA), body composition (DXA). After 
approximately 30-min rest testing, resting blood pressure (BP) and resting heart rate (HR) 
were tested. 
Following those testing, participants had 5-min break. After then cognitive 
function tests (Stroop Test) and Readiness to Perform Visual Analogue Scale (RTP-VAS) 
were tested, and they continued to perform bench and leg press, and Wingate 30s test. 
Figure 6 shows the timeline of testing procedures. 
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Table 2. Study 2 Protocol Overview 
 
 
Supplementation Protocol  
Following baseline testing, participants entering this phase of the trial were 
matched for age, body mass, fat free mass (FFM), and training history and subsequently 
randomized to receive a PLA, PWS and PWS+S as described above. Participants were 
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assigned in a double-blind and counter-balanced manner and asked to ingest 12 g of 
supplements with 235 ml of water; once daily approximately 15-30 min prior to exercise 
on training day and approximately same time every day in the morning with breakfast on 
non-training day. 
 
 
Figure 6. Study 2 Timeline of Measurement Procedures 
 
Training Protocol 
Unlike Study 1, all participants were required to follow the same resistance 
training routine during Study 2. The resistance training routine consisted of exercise 4-d 
per week split into two upper and two lower body workouts per week for a total of 8-
weeks. The 8-wk training protocol was periodized in 3-wk increments consisting of 
selected exercises for the following muscle groups: chest (two exercises for a total of six 
sets), back (two exercise for a total of six sets), shoulders (one exercise for a total of three 
sets), biceps (one exercise for a total of three sets), triceps  (one exercise for a total of three 
sets), abdominals (one exercise for a total of three sets), quadriceps (two exercises for a 
total of six sets), hamstrings (two exercises for a total of six sets), and calves (one exercise 
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for three sets). Each exercise consisted of three sets of 10 repetitions (wk 1-3), 8 repetitions 
(wk 4-6), or 6 repetitions (wk 7-8) performed with as much weight as the participant could 
perform per set. Training logs were completed and maintained by each participant. The 
participants recorded the amount of weight lifted during each set on a training log. A 
training partner or fitness instructor who signed off the session monitored training sessions. 
Table 3 and Table 4 present the training logs of upper and lower body workout, 
respectively. 
Food Frequency Record 
 All participants were required to record their food consumption of 4-day a week 
before at each testing session and instructed to record everything they ate for 3 weekdays 
and 1 weekend day. Further, participants were asked to precisely record the food item 
(brand if applicable), preparation method, and total quantity consumed. Table 5 shows the 
daily food-log table. 
Testing Procedures at Week 4 and Week 8 
Same as baseline testing procedure, participants were instructed to refrain from 
exercise, caffeine, and supplements/medications containing stimulants for 48-h prior to 
testing. Participants presented to the lab after a 12-h fast and were required to provide 4-
d food-log, training-log, and weekly follow-up report. Once checked in, participants 
donated ~ 20 ml of blood via venipuncture, and we administered a series of tests: body 
weight, body water (BIA), body composition (DXA), resting BP, resting HR, Stroop Test 
and RTP-VAS test, bench and leg press, and Wingate 30s test. These testing were repeated 
at week 4 (mid-supplementation) and week 8 (post-supplementation).
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Table 3. Study 2 Training-log for Upper Body 
 
43 
 
Table 4. Study 2 Training-log for Lower Body  
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Table 5. Study 2 Daily Food-log Sheet
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Testing Methodologies 
Anthropometry: For Study 2, body composition was tested at baseline, week 4 and 
week 8. Body mass and height, and body composition were determined using an auto-
calibrated scale with a Dual Energy X-Ray Absorptiometer (DXA) excluding cranium as 
the same model and protocol used for Study 1. Test/retest reliability studies performed on 
male athletes with DXA yielded mean deviation for total bone mineral content and total 
fat-free-soft tissue mass of 0.31-0.45%, with a mean intra-class correlations of 0.985 [174]. 
Blood Chemistry: At each testing session, blood sample was collected with 12-h 
fasting once participants presented. All blood samples were analyzed with the same 
methods of Study 1. The internal quality control for the Cobas® c111 was performed using 
two levels of control fluids purchased from manufacturer to calibrate acceptable SD and 
coefficients of variation values for all aforementioned assays, and the one of Abbott Cell 
Dyn 1800 was performed using three levels of control fluids purchased from manufacturer 
to calibrate acceptable Cv values for all whole blood cell parameters (± 6.27%). 
Blood Pressure and Heart Rate Assessment: Resting BP and resting HR were 
determined by palpation of the radial artery using standard procedures and aneroid 
sphygmomanometer. Blood pressure was also assessed using standard auscultatory 
procedures [176].  
Cognitive Function and Readiness to Perform: Cognitive function and RTP-VAS 
were tested the same way of Study 1 with Stroop Word-Color test standardized by Golden 
[177] and with five subjective feeling (strongly disagree to strongly agree) on 20 cm dotted 
bar, respectively. 
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1RM Bench and Leg Press Testing: BP-1RM and LP-1RM testing procedure of 
Study 2 were performed using the same as Study 1 at familiarization. Previously 
mentioned, research in our lab on resistance-trained participants has yielded a low day-to-
day mean coefficients of variation and high reliability for the bench press (1.1%, intra-
class, r = 0.99). 
Wingate Anaerobic Capacity Testing: Wingate testing was assessed using the 
same ergometer as Study 1 and work rate was set at of 7.5 J/kg/rev. Participants were 
asked to pedal as fast as possible prior to application of the workload and sprint at an all-
out maximal capacity for 30-sec Wingate test. Test-to-test variability in performing 
repeated Wingate anaerobic capacity tests in our lab have yielded correlation coefficients 
of r = 0.98±15% for mean power. 
Food Frequency: All food logs were entered and analyzed by a registered dietitian 
using dietary analysis software (ESHA Food Processor Version 8.6, Salem, OR). 
Training Volume: Total lifting volume was calculated for each subject per 
exercise session and for the entire training program.  
Side Effects: The side effects questionnaire was completed every week of 
supplementation during chronic supplementation (Table 6). The questionnaire was 
completed to determine how well participants tolerated supplementation; how well 
participants followed the supplementation protocol; and if participants experienced any 
symptoms during the supplementation period. Participants were asked to rank the 
frequency and severity of their symptoms – dizziness, headache, fast or racing heart rate, 
heart skipping or palpitations, shortness of breath, nervousness, blurred vision, and 
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unusual or adverse effects. Participants were asked to rank their symptoms with 0 (none), 
1 (minimal: 1-2/wk), 2 (slight: 3-4/wk), 3 (occasional: 5-6/wk), 4 (frequent: 7-8/wk), or 5 
(severe: 9 or more/wk). 
 
Table 6. Study 2 Side Effects Questionnaire 
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Statistical Analysis 
Study 1 
The primary outcomes included readiness to perform and cognitive function. 
Secondary outcomes included all respective indices of resistance and Wingate exercise 
performance testing. Tertiary outcomes included REE, HR, BP and all hematological 
markers obtained over the testing period. In REE, area under the curve (AUC) of O2, 
CO2, and RER were calculated by summing up response by every 1-min for 30-min post-
ingestion of supplement. AUC were computed on REE data by Prism 6 (GraphPad 
Software Inc., La Jolla, CA, USA) calculating the trapezoid rule and analyzed by ANOVA. 
All data were analyzed using general linear model Multivariate Analysis of Variance 
(MANOVA) with Wilks Lambda and Greenhouse Geisser adjustments by the statistical 
software SPSS 22.0 (IBM Corporation, Armonk, NY, USA). Between group comparisons 
were made using a Dunnet-Hsu post-hoc assessment vs. the PLA condition and all data 
are presented as mean ± SD. Data were considered significantly different when the 
probability of error was 0.05 or less with trends noted when p-levels ranged between p > 
0.05 to p < 0.05. 
Study 2 
The primary outcomes included all respective indices of strength and Wingate 
anaerobic performance testing. Secondary outcomes included measurements assessing 
readiness to perform and cognitive function. Tertiary outcomes included resting heart rate, 
resting blood pressure, and all hematological markers obtained over the testing period. 
With regard to hematology, we also pursued analyses denoting changes from normal to 
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exceeding normal clinical limits from baseline to week 4, baseline to week 8 and week 4 
to week 8 using a Chi-square analysis. All data were analyzed using general linear models 
with Wilks Lambda and Greenhouse Geisser adjustments by the statistical software SPSS 
22.0. Between group comparisons were made using a Dunnet-Hsu post-hoc assessment vs. 
the PLA condition and all data are presented as mean ± SD or mean change and 95% CI.  
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 CHAPTER IV 
RESULTS 
Study 1: Acute Supplementation 
Participant Demographics 
Figure 7 presents a CONSORT schematic for Study 1. 26 participants were 
initially recruited for Study 1, completed consent forms, and participated in the required 
familiarization session. Of the original 26 participants, 25 participants completed Study 1, 
one participant dropped out after the first testing session due to deny of testing. Table 7 
presents Study 1 participant demographics. 
 
 
Figure 7. Study 1 - Consort Schematic of Enrollment and Treatment Allocation 
51 
 
Table 7. Study 1 - Participant Demographics 
       
N Age Height  Body Weight BMI Lean Mass Body Fat 
 (y) (cm) (kg) (kg/m2) (kg) (%) 
              
25 21.7 ± 3.0 176.1 ± 8.2 78.2 ± 13.09 25.0 ± 3.0 58.7 ± 11.1 15.2 ± 5.2 
              
 
Metabolic Responses 
Figure 8 shows minute-by-minute comparison of (a) O2, (b) CO2, and (c) RER, 
for 30-min post-supplementation. Overall, we observed minor, yet significant changes in 
AUC results for oxygen uptake ( O2), carbon dioxide production ( CO2), as well as RER 
averaged over the last 5-min of the REE assessment.  
  
 
Figure 8a. Study 1 – Minute-by-minute Comparison of O2 Change 
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Figure 8b. Study 1 – Minute-by-minute Comparison of CO2 Change 
 
  
Figure 8c. Study 1 – Minute-by-minute Comparison of RER Change 
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The AUC for O2 was PWS+S (1,034 ± 584 ml/30min), PWS (802 ± 434 
ml/30min), and PLA (684 ± 376 ml/30min) (Fig. 9a). The AUC for CO2 was PWS+S 
(1,372 ± 604 ml/30min), PWS (1,151 ± 673 ml/30min), and PLA (634 ± 262 ml/30min) 
(Fig. 9b). RER averaged over the last 5min of the REE assessment showed several 
significant differences vs. PLA (Fig. 9c). Specifically, the PLA (0.89 ± 0.09) was different 
from PWS (0.92 ± 0.06, p < 0.02) and PWS+S (0.85 ± 0.04, p = 0.006) and PWS was 
significantly different to PWS+S (p < 0.001). Despite these perturbations in resting 
metabolism, no significant differences were noted for REE throughout the 30min 
measurement period: PWS+S (39.65 ± 9.31 kcal/30min), PWS (40.18 ± 8.97 kcal/30min) 
and PLA (39.13 ± 5.78 kcals/30min). The results from the O2, CO2, and RER analysis 
provides supporting evidence which accepted the null hypothesis of hypothesis 1 which 
stated that there will be significant differences of  O2,  CO2, and RER among groups 
for 30-min post-ingestion. 
Cognitive Function and Readiness to Perform 
 Table 8 and Table 9 show cognitive function and readiness to perform results, 
respectively. Significant increases were observed in response to “I feel vigorous and 
energetic” for the PWS (p = 0.02), PWS+S (p = 0.02) but not for the PLA (p = 0.80). Also, 
we found that the mean change in “I am optimistic about my future performance” (p = 
0.02), and in “I feel vigorous and energetic” (p < 0.01) were significantly increased one 
hour following supplementation. The results from the cognitive function and readiness to 
perform test analysis provides supporting evidence which accepted the null hypothesis of 
hypothesis 2 and hypothesis 3 which stated that there will be significant differences of 
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Figure 9a. Study 1 – Area Under the Curve of O2. Data are mean ± SD. 
 
 
Figure 9b. Study 1 – Area Under the Curve of CO2. Data are mean ± SD.  
(a) AUC of O2 for 30min post-supplementation 
(b) AUC of CO2 for 30min post-supplementation 
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Figure 9c. Study 1 – RER averaged over the last 5-min. Data are mean ± SD. Statistical 
notations represent - a Significantly different from PWS (p < 0.02) and PWS+S (p = 0.006) 
and b significantly different from PWS+S (p < 0.001). 
 
cognitive function with Stroop Word-Color test prior to, during, and post-supplementation 
and there will be significant differences of RTP-VAS among groups prior to, during, and 
post-supplementation, respectively. 
Exercise Performance 
We did not observe any significant differences for bench press lifting volume (PLA: 
2,166 ± 718; PWS: 2,217 ± 732; PWS+S: 2,268 ± 809 kg; p = 0.10) and leg press lifting 
volume (PLA: 12,550 ± 4,321; PWS: 13,139 ± 4,409; PWS+S: 12,701 ± 3,866 kg; p = 
0.30). The results from the bench and leg press test analysis provides supporting evidence 
(c) RER Averaged Over the Last 5-min 
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Table 8. Study 1 - Stroop Word-Color Test 
      
Variable  Group 
Time (h) 
Mean ± SE 
 
p-level 
0 1 2   
Word (counts) PWS+S 104.8 ± 11.4 b,c 115.0 ± 13.6 b,c 116.8 ± 14.4 b,c 112.2 ± 2.4 b,c Group < 0.001 
 PWS 116.7 ± 15.5 a,c 119.5 ± 15.4 a 124.6 ± 17.7 a 120.2 ± 3.0 a Time < 0.001 
 PLA 120.9 ± 15.7 a,b 121.1 ± 16.6 a 122.6 ± 18.0 a 121.5 ± 3.1 a G x T < 0.001 
 Mean ± SE 114.1 ± 2.6 118.5 ± 2.9 * 121.3 ± 3.1 *^    
Color (counts) PWS+S 79.7 ± 10.5 b,c 84.9 ± 11.7 b,c 89.8 ± 12.5 b 84.8 ± 2.2 b,c Group 0.01 
 PWS 91.2 ± 21.3 a 95.1 ± 19.9 a  99.4 ± 21.0 a 95.2 ± 4.0 a Time < 0.001 
 PLA 89.9 ± 12.4 a 90.2 ± 13.6 a 93.8 ± 17.1 91.3 ± 2.7 a G x T 0.02 
 Mean ± SE 86.9 ± 2.4 90.1 ± 2.3 * 94.3 ± 2.7 *^    
Word-Color PWS+S 52.4 ± 10.6 b,c 57.0 ± 10.4 b,c 64.0 ± 10.8 b,c 57.8 ± 1.9 b,c Group < 0.001 
(counts) PWS 67.5 ± 20.3 a 70.2 ± 21.6 a 74.6 ± 18.9 a 70.8 ± 4.0 a Time < 0.001 
 PLA 66.4 ± 9.6 
a 66.8 ± 14.9 a 71.3 ± 11.7 a 68.2 ± 2.2 a G x T 0.03 
 Mean ± SE 62.1 ± 2.1 64.7 ± 2.4 * 69.9 ± 1.9 *^    
Values are means ± standard deviations. Word, Color, and Word-Color counts were analyzed by MANOVA. MANOVA 
analysis revealed overall Wilks' Lambda group (p<0.001), time (p<0.001), and group x time (p<0.001). Greenhouse-Geisser 
time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. a denotes a significant 
difference from PWS+S. b denotes a significant difference from PWS. c denotes a significant difference from PLA. * 
represents p<0.05 difference from baseline. ^ represents p<0.05 difference from 1-hr. 
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Table 9. Study 1 - Readiness to Perform Visual Analogue Scale       
Questions Group 
Time (h) 
Mean ± SE 
 
p-level 
0 1 2   
I slept well last night PWS+S 3.51 ± 0.73 3.52 ± 0.73 3.63 ± 0.74 3.55 ± 0.14 Group 0.23 
 PWS 3.47 ± 0.61 3.63 ± 0.56 3.59 ± 0.67 3.57 ± 0.11 Time 0.29 
 PLA 3.35 ± 0.72 3.33 ± 0.72 3.31 ± 0.84 3.33 ± 0.14 G x T 0.17 
 Mean ± SE 3.44 ± 0.09 3.49 ± 0.10 3.51 ± 0.12    
I am looking forward to today's workout PWS+S 3.71 ± 0.99 3.82 ± 1.17 3.51 ± 1.09 3.68 ± 0.20 Group 0.61 
 PWS 3.71 ± 0.77 3.89 ± 0.79  3.65 ± 0.65  3.75 ± 0.13 Time 0.04 
 PLA 3.67 ± 0.85 3.61 ± 1.00 3.61 ± 0.87 3.63 ± 0.17 G x T 0.20 
 Mean ± SE 3.69 ± 0.15 3.77 ± 0.17 3.87 ± 0.13 ^    
I am optimistic about my future performance PWS+S 4.00 ± 0.69 4.21 ± 0.62 4.01 ± 0.71 4.07 ± 0.12 c Group 0.01 
 PWS 3.88 ± 0.69 4.05 ± 0.73 3.83 ± 0.70 3.92 ± 0.12 Time 0.03 
 PLA 3.74 ± 0.83 3.70 ± 0.94 3.78 ± 0.88 3.74 ± 0.17 
a G x T 0.19 
 Mean ± SE 3.87 ± 0.13 3.99 ± 0.13 * 3.87 ± 0.13    
I feel vigorous and energetic PWS+S 3.33 ± 0.77 3.89 ± 0.73 c 2.96 ± 0.97 b,c 3.39 ± 0.13 Group 0.55 
 PWS 3.19 ± 0.89 3.77 ± 0.78 
c 3.33 ± 1.09 a 3.43 ± 0.14 Time 0.03 
 PLA 3.23 ± 0.95 3.35 ± 0.90 
a,b 3.38 ± 1.04 a 3.32 ± 0.17 G x T <0.001 
 Mean ± SE 3.25 ± 0.16 3.67 ± 0.12 * 3.22 ± 0.18 ^    
My appetite is great PWS+S 3.80 ± 0.98 3.79 ± 0.89 3.57 ± 0.97 3.72 ± 0.16 Group 0.32 
 PWS 3.63 ± 0.86 3.49 ± 0.91 3.43 ± 0.83 3.52 ± 0.14 Time 0.36 
 PLA 3.73 ± 0.85 3.55 ± 0.86 3.57 ± 0.87 3.62 ± 0.14 G x T 0.43 
 Mean ± SE 3.72 ± 0.15 3.61 ± 0.15 3.52 ± 0.15    
I have little muscle soreness PWS+S 3.13 ± 1.31 3.27 ± 1.28 3.21 ± 1.12 3.20 ± 0.21 Group 0.16 
 PWS 3.54 ± 1.17 3.81 ± 1.35 3.25 ± 1.03 3.53 ± 0.21 Time 0.17 
 PLA 3.60 ± 0.99 3.42 ± 0.99 3.29 ± 1.01 3.44 ± 0.16 G x T 0.16 
 Mean ± SE 3.43 ± 0.17 3.50 ± 0.21 3.25 ± 0.18    
Values are means ± standard deviations. Six questions were analyzed by MANOVA. MANOVA analysis revealed overall Wilks' Lambda group (p=0.03), time 
(p=0.04), and group x time (p=0.007). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. a denotes a 
significant difference from PWS+S. b denotes a significant difference from PWS. c denotes a significant difference from PLA. * represents p<0.05 difference from 
baseline. ^ represents p<0.05 difference from 1-hr. 
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which rejected the null hypothesis of hypothesis 4 and hypothesis 5 which stated that there 
will be significant differences of upper body strength with bench press test among groups 
after supplementation and there will be significant differences of lower body strength with 
leg press test among groups after supplementation, respectively. 
Similarly, no significant differences were found in between groups Wingate peak 
power (PLA: 19.89 ± 5.14; PWS: 19.03 ± 5.29; PWS+S: 18.86 ± 5.22 Watt/kg; p = 0.51), 
mean power (PLA: 7.68 ± 1.08; PWS: 7.66 ± 1.27; PWS+S: 7.76 ± 1.33 Watt/kg; p = 
0.77), or total work (PLA: 17,662 ± 4,605; PWS: 17,850 ± 4,340; PWS+S: 18,203 ± 4,658 
Joules; p = 0.49). The results from the Wingate anaerobic sprint test analysis provides 
supporting evidence which rejected the null hypothesis of hypothesis 6 which stated that 
there will be significant differences of anaerobic capacity with WAT among groups after 
supplementation. 
Blood Pressure and Heart Rate Responses 
No significant treatment effects over 30 minutes were observed from un-
supplemented baseline HR: PWS+S (57.9 ± 1.3 b/min), PWS (56.5 ± 1.3 b/min), PLA 
(59.5 ± 1.4 b/min), systolic blood pressure PWS+S (113.4 ± 1.6 mmHg), PWS (112.4 ± 
1.4 mmHg), PLA (113.6 ± 1.2 mmHg) or diastolic blood pressure PWS+S (70.0 ± 1.3 
mmHg), PWS (70.3 ± 1.3 mmHg), PLA (69.2 ± 1.2 mmHg) following treatment ingestion 
(Table 10). The results from the HR, SBP, and DBP test analysis provides supporting 
evidence which accepted the null hypothesis of hypothesis 7 which stated that there will 
be no significant differences of resting heart rate and blood pressure among groups prior 
to, during, and post-supplementation. 
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Hematologic Responses 
Results of blood analyses are presented in Table 11. Overall, we observed several 
significant changes in various blood markers during the 2-h post-supplementation 
following a series of exercise tests; however, the changes as a whole were random in 
nature and inconsistent amongst and between groups. The results from the blood chemistry 
test analysis provides supporting evidence which rejected the null hypothesis of 
hypothesis 8 and 10 which stated that there will be no significant differences of blood 
metabolic markers; cholesterol, HDL-C, LDL-C, glucose among groups prior to and 2-hr 
post supplementation, and there will be no significant differences of kidney enzymes, CRE 
and BUN among groups prior to and 2-hr post supplementation, respectively. In contrast, 
the results from the blood chemistry test analysis provides supporting evidence which 
accepted the null hypothesis of hypothesis 9 and 11 which stated that there will be no 
significant differences of muscle enzymes, LDH and CK among groups prior to and 2-hr 
post supplementation, and there will be no significant differences of liver enzymes; ALP, 
ALT, and AST among groups prior to and 2-hr post supplementation, respectively. 
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Table 10. Study 1 - Heart Rate and Blood Pressure Response 
Variable  Group 
Time (min) 
Mean ± SE 
 
p-level 
Pre 0 10 20 30   
HR 
(beats/min) 
PWS+S 56.6 ± 7.2 57.5 ± 8.8 56.5 ± 9.5 58.4 ± 9.1 60.4 ± 10.8 57.9 ± 1.3 Group 0.11 
 PWS 55.5 ± 7.3 58.2 ± 9.5 54.2 ± 7.2 56.5 ± 7.7 58.1 ± 8.1 56.5 ± 1.3 Time < 0.001 
 PLA 58.2 ± 9.5 60.4 ± 8.1 58.6 ± 8.5 59.6 ± 8.3 60.6 ± 8.4 59.5 ± 1.4 G x T 0.83 
 Mean ± SE 56.8 ± 1.1 58.7 ± 1.2 * 56.4 ± 1.3 ^ 58.2 ± 1.1 59.7 ± 1.3 *
#       
SBP (mmHg) PWS+S 113.1 ± 7.8 112.5 ± 8.3 113.0 ± 9.6 113.9 ± 10.6 114.6 ± 10.0 113.4 ± 1.6 Group 0.55 
 PWS 111.5 ± 7.1 112.4 ± 7.3 112.9 ± 8.6 112.8 ± 7.9 112.5 ± 8.2 112.4 ± 1.4 Time 0.31 
 PLA 113.3 ± 7.6 114.3 ± 8.0 112.7 ± 6.8 114.3 ± 6.3 113.6 ± 6.6 113.6 ± 1.2 G x T 0.52 
 Mean ± SE 112.6 ± 1.2 113.1 ± 1.3 112.8 ± 1.3 113.6 ± 1.3 113.5 ± 1.3       
DBP 
(mmHg) 
PWS+S 69.6 ± 7.2 70.0 ± 6.7 71.0 ± 6.8 71.1 ± 8.1 68.4 ± 13.0 70.0 ± 1.3 Group 0.76 
 PWS 69.0 ± 6.7 70.7 ± 6.1 70.9 ± 7.1 70.6 ± 7.5 70.4 ± 7.7 70.3 ± 1.3 Time 0.45 
 PLA 69.6 ± 6.8 69.2 ± 6.5 68.8 ± 6.3 69.5 ± 7.4 69.1 ± 7.1 69.2 ± 1.2 G x T 0.50 
 Mean ± SE 69.4 ± 0.8 69.9 ± 0.8 70.2 ± 1.0 70.4 ± 1.1 69.3 ± 1.2    
Values are means ± standard deviations. Heart Rate (HR), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) were 
analyzed by MANOVA. MANOVA analysis revealed overall Wilks' Lambda group (p=0.27), time (p=0.03), and group x time (p=0.81). 
Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. a denotes a 
significant difference from PWS+S. b denotes a significant difference from PWS. c denotes a significant difference from PLA. * 
represents p<0.05 difference from pre-supplementation. ^ represents p<0.05 difference from 0-min. # represents p<0.05 difference from 
10-min. 
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Table 11. Study 1 - Hematological Response 
Variable Group Time (h) 
Mean ± SE p-level 
0 2 
ALP PWS+S 75.0 ± 19.2 82.2 ± 23.0 78.6 ± 4.2 Group 0.27 
(U/L) PWS 77.7 ± 31.1 82.3 ± 22.5 80.0 ± 5.3 Time < 0.001 
PLA 79.8 ± 21.7 85.7 ± 27.5 82.7 ± 4.9 G x T 0.69 
Mean ± SE 77.5 ± 4.5 83.4 ± 4.7 * 
ALT PWS+S 25.7 ± 11.7 27.1 ± 10.1 26.4 ± 2.0 Group 0.43 
(U/L) PWS 24.5 ± 11.0 28.0 ± 12.2 26.2 ± 2.3 Time < 0.001 
PLA 29.5 ± 27.6 33.3 ± 32.9 31.4 ± 6.1 G x T 0.26 
Mean ± SE 26.6 ± 2.5 29.5 ± 2.8 * 
AST PWS+S 25.3 ± 6.6 28.8 ± 6.5 27.1 ± 1.3 Group 0.31 
(U/L) PWS 24.9 ± 6.2 29.6 ± 7.1 27.3 ± 1.3 Time < 0.001 
PLA 38.1 ± 60.6 44.9 ± 75.7 41.5 ± 13.9 G x T 0.37 
Mean ± SE 29.5 ± 4.2 34.4 ± 5.2 * 
BUN PWS+S 16.4 ± 4.0 15.9 ± 3.5 16.1 ± 0.7 Group 0.22 
(mg/dl) PWS 17.4 ± 4.7 15.1 ± 3.7 16.2 ± 0.8 Time < 0.001 
PLA 15.9 ± 4.8 14.4 ± 4.1 15.1 ± 0.9 G x T 0.01 
Mean ± SE 16.6 ± 0.7 15.1 ± 0.6 * 
Creatinine PWS+S 0.97 ± 0.14 b 1.11 ± 0.17 b,c 1.04 ± 0.03 b Group < 0.001 
(mg/dl) PWS 1.09 ± 0.17 
a,c 1.23 ± 0.17 a,c 1.16 ± 0.03 a,c Time < 0.001 
PLA 0.99 ± 0.14 b 1.05 ± 0.16 a,b 1.02 ± 0.03 b G x T 0.03 
Mean ± SE 1.02 ± 0.02 1.13 ± 0.03 * 
BUN:Creatinine PWS+S 17.1 ± 4.8 14.4 ± 3.4 c 15.7 ± 0.8 Group 0.18 
PWS 16.2 ± 5.0 12.3 ± 3.2 a,c 14.3 ± 0.8 Time < 0.001 
PLA 16.2 ± 5.9 13.9 ± 4.9 b 15.1 ± 1.1 G x T < 0.001 
Mean ± SE 16.5 ± 0.9 13.5 ± 0.6 * 
Values are means ± standard deviations. ALP, ALT, AST, BUN, Creatinine, ratio of BUN to Creatinine, 
Cholesterol, HDL-C, ratio of Cholesterol to HDLC, LDL-C, Triglyceride, CK, LDH, and Glucose were analyzed 
by MANOVA. MANOVA analysis revealed overall Wilks' Lambda group (p<0.001), time (p<0.001), and group x 
time (p<0.001). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate 
group p-levels. a denotes a significant difference from PWS+S. b denotes a significant difference from PWS. c 
denotes a significant difference from PLA. * represents p<0.05 difference from baseline. 
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Table 11. Continued 
 
      
Variable  Group Time (h) 
Mean ± SE 
 
p-level 
    0 2   
Cholesterol PWS+S 161.7 ± 29.8 b,c 174.0 ± 33.5 c 167.8 ± 6.3 b,c Group < 0.001 
(mg/dl) PWS 187.3 ± 46.6 
a,c 180.2 ± 36.9 183.7 ± 8.1 a Time < 0.001 
 PLA 170.6 ± 34.6 
a,b 182.8 ± 35.1 a 176.7 ± 7.0 a G x T < 0.001 
 Mean ± SE 173.2 ± 6.7 179.0 ± 6.9 *    
HDL-C PWS+S 54.2 ± 16.2 60.1 ± 18.1 57.2 ± 3.4 Group 0.50 
(mg/dl) PWS 52.2 ± 13.9 58.9 ± 14.6 55.5 ± 2.9 Time < 0.001 
 PLA 54.9 ± 13.3 60.1 ± 16.0 57.5 ± 2.8 G x T 0.57 
 Mean ± SE 53.8 ± 2.7 59.7 ± 3.1 *       
CHOL:HDL PWS+S 3.2 ± 1.0 b 3.1 ± 1.0 3.1 ± 0.2 b Group < 0.001 
 PWS 3.8 ± 1.3 
a,c 3.2 ± 1.0 3.5 ± 0.2 a,c Time < 0.001 
 PLA 3.2 ± 0.9 
b 3.2 ± 0.9 3.2 ± 0.1 b G x T < 0.001 
 Mean ± SE 3.4 ± 0.2 3.1 ± 0.1 *       
LDL-C PWS+S 99.8 ± 41.2 104.6 ± 40.7 102.2 ± 8.2 Group 0.18 
(mg/dl) PWS 96.9 ± 31.9 104.5 ± 36.0 100.7 ± 6.9 Time < 0.001 
 PLA 104.3 ± 36.7 109.6 ± 41.2 107.0 ± 7.8 G x T 0.56 
 Mean ± SE 100.3 ± 7.2 106.3 ± 7.7 *       
Triglyceride PWS+S 88.3 ± 42.2 92.8 ± 54.6 90.5 ± 9.6 Group 0.25 
(mg/dl) PWS 109.5 ± 56.8 100.3 ± 47.5 104.9 ± 10.1 Time 0.37 
 PLA 98.00 ± 58.6 89.3 ± 38.3 93.6 ± 9.3 G x T 0.13 
 Mean ± SE 98.6 ± 8.9 94.1 ± 8.2     
CK PWS+S 189.2 ± 85.4 222.5 ± 84.6 205.9 ± 17.1 Group 0.29 
(U/L) PWS 191.4 ± 104.1 230.8 ± 111.3 211.1 ± 21.9 Time 0.03 
 PLA 713.3 ± 2354.3 836.4 ± 2785.6 774.8 ± 524.6 G x T 0.33 
 Mean ± SE 364.6 ± 160.4 429.9 ± 190.0 *       
LDH PWS+S 166.9 ± 25.5 192.2 ± 24.2 179.5 ± 4.8 Group 0.35 
(U/L) PWS 160.65 ± 18.0 186.7 ± 22.2 173.6 ± 3.9 Time < 0.001 
 PLA 181.7 ± 76.8 205.4 ± 114.7 193.5 ± 19.4 G x T 0.87 
 Mean ± SE 169.7 ± 6.6 194.8 ± 9.1 *      
Glucose PWS+S 90.4 ± 7.3 b 113.8 ± 15.0 c 102.1 ± 1.9 b,c Group < 0.001 
(mg/dl) PWS 100.1 ± 16.0 
a,c 114.4 ± 12.6 c 107.3 ± 1.9 a,c Time < 0.001 
 PLA 90.2 ± 9.7 
b 101.5 ± 14.4 a,b 95.8 ± 2.0 a,b G x T 0.03 
 Mean ± SE 93.6 ± 1.4 109.9 ± 2.2 *    
Values are means ± standard deviations. ALP, ALT, AST, BUN, Creatinine, ratio of BUN to Creatinine, Cholesterol, 
HDL-C, ratio of Cholesterol to HDLC, LDL-C, Triglyceride, CK, LDH, and Glucose were analyzed by MANOVA. 
MANOVA analysis revealed overall Wilks' Lambda group (p<0.001), time (p<0.001), and group x time (p<0.001). 
Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. a 
denotes a significant difference from PWS+S. b denotes a significant difference from PWS. c denotes a significant 
difference from PLA. * represents p<0.05 difference from baseline. 
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Study 2: Chronic Supplementation 
Participant Demographics 
Figure 10 presents a CONSORT schematic for Study 2. 122 participants were 
initially recruited for Study 2, completed consent forms, and participated in the required 
familiarization session. Of the original 122 participants, 80 participants completed Study 
2. Table 12 presents Study 2 participant demographics. 
 
 
Figure 10. Study 2 Consort Schematic of Enrollment and Treatment Allocation 
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Table 12. Study 2 - Participant Demographics   
Variable  Group N Values p-level 
Age (y) PWS+S 26 22.0 ± 2.6 0.31 
 PWS 27 20.9 ± 3.9  
 PLA 27 22.3 ± 3.9   
Height (cm) PWS+S 26 177.8 ± 5.6 0.64 
 PWS 27 177.0 ± 4.6  
 PLA 27 178.4 ± 6.9   
Body Weight (kg) PWS+S 26 80.2 ± 15.8 0.94 
 PWS 27 81.5 ± 13.0  
 PLA 27 81.1 ± 13.3   
BMI (kg/m2) PWS+S 26 25.4 ± 3.4 0.72 
 PWS 27 26.1 ± 4.6  
 PLA 27 25.4 ± 3.4  
Values are means ± standard deviations. Variables were analyzed by one-way ANOVA. 
 
Training and Dietary Characteristics 
Table 13 presents total training volume of upper and lower body for 8-wk. No 
significant differences were noted for total training volume over the eight-week study 
period: PLA (550321 ± 287503 kg), PWS (520515 ± 169245 kg) PWS+S (509392 ± 
280566 kg). The results from the training volume analysis provides supporting evidence 
which accepted the null hypothesis of hypothesis 12 which stated that there will be no 
significant differences of training volume of upper and lower body among groups over 8-
wk following supplementation. 
Participants presented to the study consuming a total of 2280.20 ± 783.86 
kcals/day, partitioned for 128.77 ± 54.47 g/d of protein, 210.58 ± 77.09 g/d of 
carbohydrate and 91.90 ± 41.08 g/d of fat averaged over 8-wk study period. No significant 
changes in diet were observed during the study period (Table 14). The results from the 
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dietary consumption analysis provides supporting evidence which accepted the null 
hypothesis of hypothesis 13 which stated that there will be no significant differences of 
consumption of macronutrient, CHO, FAT, and PRO, among groups over 8-wk following 
supplementation. 
Table 13. Study 2 - Total Workout Volume for 8 Week 
Variable Group N Total Volume p-level 
Upper body (kg) PWS+S 23 269928 ± 103130 0.32 
PWS 27 236691 ± 87062 
PLA 25 279831 ± 132101 
Lower body (kg) PWS+S 23 305906 ± 133611 0.65 
PWS 27 283825 ± 100541 
PLA 25 314516 ± 136966 
Values are means ± standard deviations. Total training volume was analyzed by one-
way MANOVA. MANOVA analysis revealed overall Wilks' Lambda group (p=0.69). 
p-levels was reported with between-subjects effects. 
Body Composition 
Table 15   shows the results from all body composition analysis. A MANOVA 
analysis was used to examine changes in body composition variables included body 
weight, fat mass, fat-free mass, and percentage of body fat. The results from the DXA 
analysis provides supporting evidence which rejected the null hypothesis of hypothesis 14 
which stated that there will be significant differences of fat mass with DXA body scan 
among groups over 8 weeks following supplementation. 
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Table 14. Study 2 - Dietary Characteristics 
      
Variable  Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
Calories (kcal/d) PWS+S 23 2277.0 ± 755.6 2285.8 ± 904.4 2514.2 ± 1129.0 2359.0 ± 140.3 Group 0.21 
 PWS 25 2464.5 ± 786.6 2083.1 ± 653.4 2178.3 ± 1025.4 2241.9 ± 134.6 Time 0.24 
 PLA 26 2124.6 ± 706.6 2011.0 ± 590.4 1944.3 ± 769.3 2026.6 ± 132.0 G x T 0.17 
 Mean ± SE  2288.7 ± 87.2 2126.7 ± 83.9 2212.3 ± 113.9    
Protein (g/d) PWS+S 23 135.9 ± 57.8 140.7 ± 79.9 138.2 ± 67.4 138.3 ± 10.4 Group 0.34 
 PWS 25 128.3 ± 49.6 112.8 ± 43.4 127.1 ± 79.8 122.7 ± 9.9 Time 0.76 
 PLA 26 117.8 ± 41.5 117.5 ± 49.0 118.3 ± 49.6 117.9 ± 9.7 G x T 0.68 
 Mean ± SE  127.3 ± 5.7 123.7 ± 6.8 127.9 ± 7.7    
Carbohydrate (g/d) PWS+S 23 203.1 ± 64.3 206.1 ± 95.5 195.0 ± 85.0 201.4 ± 13.3 Group 0.84 
 PWS 25 231.7 ± 90.6 197.3 ± 76.6 187.7 ± 88.0 205.6 ± 12.8 Time 0.02 
 PLA 26 204.9 ± 75.2 204.4 ± 68.7 175.8 ± 68.4 195.0 ± 12.5 G x T 0.38 
 Mean ± SE  213.2 ± 9.0 202.6 ± 9.3 186.2 ± 9.3 *    
Fat (g/d) PWS+S 23 93.6 ± 39.7 93.6 ± 61.2 101.5 ± 49.6 96.2 ± 6.8 c Group 0.80 
 PWS 25 100.8 ± 38.9 85.6 ± 38.8 95.1 ± 49.0 93.8 ± 6.5 Time 0.24 
 PLA 26 82.3 ± 36.9 70.8 ± 27.1 77.5 ± 43.3 76.9 ± 6.4 
a G x T 0.80 
 Mean ± SE   92.2 ± 4.4 83.4 ± 5.1 91.4 ± 5.5       
Values are means ± standard deviations. Total calories, Protein, Carbohydrate, and Fat intake were analyzed by MANOVA. MANOVA 
analysis revealed overall Wilks' Lambda group (p=0.04), time (p=0.03), and group x time (p=0.35). Greenhouse-Geisser time and group 
x time (G x T) interaction p-levels are reported with univariate group p-levels. * represents p<0.05 difference from baseline. ^ 
represents p<0.05 difference from wk 4. 
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Table 14. Continued 
      
Variable  Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
Calories (kcal/d/kg) PWS+S 23 29.03 ± 9.73 29.35 ± 13.75 32.13 ± 16.48 30.17 ± 2.03 Group 0.27 
 PWS 25 30.15 ± 8.76 25.72 ± 8.10 26.29 ± 10.99 27.39 ± 1.94 Time 0.29 
 PLA 26 27.06 ± 10.94 25.33 ± 9.31 24.72 ± 13.50 25.70 ± 1.90 G x T 0.19 
 Mean ± SE  28.75 ± 1.15 26.80 ± 1.22 27.71 ± 1.60    
Protein (g/d/kg) PWS+S 23 1.74 ± 0.79 1.83 ± 1.13 1.77 ± 0.94 1.78 ± 0.13 Group 0.18 
 PWS 25 1.54 ± 0.50 1.37 ± 0.47 1.51 ± 0.84 1.47 ± 0.13 Time 0.86 
 PLA 26 1.48 ± 0.57 1.46 ± 0.64 1.49 ± 0.79 1.48 ± 0.12 G x T 0.72 
 Mean ± SE  1.59 ± 0.07 1.55 ± 0.09 1.59 ± 0.10    
Carbohydrate (g/d/kg) PWS+S 23 2.61 ± 0.89 2.64 ± 1.43 2.42 ± 1.17 2.56 ± 0.19 Group 0.91 
 PWS 25 2.87 ± 1.10 2.46 ± 1.02 2.30 ± 1.00 2.55 ± 0.18 Time 0.008 
 PLA 26 2.60 ± 1.11 2.56 ± 0.95 2.21 ± 1.10 2.46 ± 0.18 G x T 0.55 
 Mean ± SE  2.70 ± 0.12 2.55 ± 0.13 2.31 ± 0.12 *^    
Fat (g/d/kg) PWS+S 23 1.19 ± 0.51 1.19 ± 0.84 1.30 ± 0.71 1.23 ± 0.09 Group 0.14 
 PWS 25 1.22 ± 0.41 1.05 ± 0.45 1.14 ± 0.52 1.14 ± 0.08 Time 0.30 
 PLA 26 1.05 ± 0.54 0.90 ± 0.41 0.98 ± 0.67 0.98 ± 0.08 G x T 0.79 
 Mean ± SE  1.15 ± 0.05 1.05 ± 0.06 1.14 ± 0.07    
Values are means ± standard deviations. Total calories, Protein, Carbohydrate, and Fat intake were analyzed by MANOVA. MANOVA 
analysis revealed overall Wilks' Lambda group (p=0.04), time (p=0.03), and group x time (p=0.35). Greenhouse-Geisser time and group 
x time (G x T) interaction p-levels are reported with univariate group p-levels. * represents p<0.05 difference from baseline. ^ 
represents p<0.05 difference from wk 4. 
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Table 15. Study 2 - Body Composition 
      
Variables Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
Body Weight PWS+S 26 80.4 ± 16.1 81.3 ± 16.7 81.8 ± 17.3 81.2 ± 2.8 Group 0.98 
(kg) PWS 27 81.8 ± 13.3 81.3 ± 11.3 82.2 ± 12.8 81.8 ± 2.7 Time < 0.01 
 PLA 27 81.1 ± 13.4 81.8 ± 14.2 82.1 ± 14.0 81.7 ± 2.7 G x T 0.27 
 Mean ± SE  81.1 ± 1.6 81.5 ± 1.5 82.1 ± 1.5 *^    
Fat Mass (kg) PWS+S 26 11.3 ± 7.3 11.6 ± 8.3 11.5 ± 8.5 11.5 ± 1.3 Group 0.75 
 PWS 27 12.7 ± 7.6 13.0 ± 7.7 12.8 ± 7.4 12.8 ± 1.3 Time 0.10 
 PLA 27 11.3 ± 5.4 11.9 ± 5.5 11.9 ± 5.2 11.7 ± 1.3 G x T 0.60 
 Mean ± SE  11.8 ± 0.7 12.1 ± 0.8 * 12.1 ± 0.8    
Fat-Free Mass PWS+S 26 62.4 ± 9.2 63.0 ± 9.0 63.6 ± 9.1 63.0 ± 1.7 Group 0.94 
(kg) PWS 27 62.3 ± 7.2 62.2 ± 6.7 62.7 ± 6.6 62.4 ± 1.7 Time < 0.01 
 PLA 27 63.0 ± 10.7 63.2 ± 11.2 63.4 ± 11.0 63.2 ± 1.7 G x T 0.28 
 Mean ± SE  62.6 ± 1.0 62.8 ± 1.0 63.2 ± 1.0 *^    
Body Fat (%) PWS+S 26 14.5 ± 5.8 14.5 ± 6.3 14.3 ± 6.1 14.4 ± 1.2 Group 0.55 
 PWS 27 16.1 ± 6.6 16.4 ± 6.7 16.2 ± 6.3 16.2 ± 1.1 Time 0.23 
 PLA 27 15.1 ± 6.2 15.7 ± 6.0 15.7 ± 5.6 15.5 ± 1.1 G x T 0.35 
 Mean ± SE  15.2 ± 0.7 15.5 ± 0.7 15.4 ± 0.6    
Values are means ± standard deviations. All variables were analyzed by MANOVA. MANOVA analysis revealed overall 
Wilks' Lambda group (p=0.06), time (p=0.03), and group x time (p=0.29). Greenhouse-Geisser time and group x time (G x 
T) interaction p-levels are reported with univariate group p-levels. a denotes a significant difference from PWS+S. b denotes 
a significant difference from PWS. c denotes a significant difference from PLA. * represents p<0.05 difference from 
baseline. ^ represents p<0.05 difference from wk 4. 
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Cognitive Function and Readiness to Perform 
Table 16 shows the results for our cognitive function testing demonstrating 
significant within group increases for Stroop Test Word, Color and Word-Color counts. 
Specific comparisons at week 4 demonstrated as significant increase in Word count for 
the PLA (3.92 counts, 95% CI 0.39, 7.45) and PWS+S (5.46 counts, 95% CI 2.09, 9.19) 
group, but not for PWS (3.21 counts, 95% CI -0.31, 6.72). By week 8 all groups increased 
their respective Word counts: PLA (6.74 counts, 95% CI 3.32, 10.16), PWS (7.56 counts, 
95% CI 4.15, 10.97) and PWS+S (9.93 counts, 95% CI 6.49, 13.73). For the Color 
assessment comparison week 4 changes are: PLA (2.77 counts, 95% CI 0.43, 5.09), PWS 
(5.05 counts, 95% CI 2.72, 7.38), and PWS+S (2.57 counts, 95% CI 0.24, 4.88). For week 
8, Color assessment changes are: PLA (4.90 counts, 95% CI 2.32, 7.46), PWS (8.33 counts, 
95% CI 5.76, 10.89) and PWS+S (5.08 counts, 95% CI 2.51, 7.63). For week 4 Word-
Color changes were significant for the PWS (3.99 counts, 95% CI 1.75, 6.23), and PWS+S 
(5.27 counts, 95% CI 3.01, 7.52), but not the PLA (2.08 counts, 95% CI -0.15, 4.31) group. 
By week 8, all groups demonstrated a significant increase in word-color counts: PLA (5.02 
counts, 95% CI 2.44, 7.59), PWS (5.84 counts, 95% CI 3.27, 8.41) and PWS+S (6.13 
counts, 95% CI 3.54, 8.72). 
However, no between group significance was otherwise noted and no differences 
were noted for any parameters denoting “Readiness to Perform” via our VAS testing 
(Table 17). The results from the Stroop Word-Color and RTP-VAS test analysis provides 
supporting evidence which rejected the null hypothesis of hypothesis 15 and 16 which 
stated that there will be significant differences of cognitive function with Stroop Word- 
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Table 16. Study 2 - Stroop Word-Color Testing Assessment       
Variable  Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
Word (counts) PWS+S 26 102.3 ± 11.2 c 108.2 ± 17.0 112.4 ± 16.1 107.6 ± 2.7 Group 0.33 
 PWS 27 107.7 ± 11.4 110.6 ± 10.9 115.3 ± 10.9 111.2 ± 2.6 Time < 0.001 
 PLA 27 109.8 ± 16.9 a 113.6 ± 17.2 116.2 ± 17.5 113.2 ± 2.6 G x T 0.45 
 Mean ± SE  106.6 ± 1.5 110.8 ± 1.7 * 114.6 ± 1.6 *^    
Color (counts) PWS+S 26 77.0 ± 10.4 79.7 ± 9.8 82.1 ± 10.8 79.6 ± 1.9 Group 0.35 
 PWS 27 78.2 ± 9.4 83.6 ± 9.6 86.7 ± 10.1 82.8 ± 1.9 Time < 0.001 
 PLA 27 80.8 ± 10.6 83.2 ± 11.8 85.7 ± 12.5 83.2 ± 1.9 G x T 0.19 
 Mean ± SE  78.7 ± 1.1 82.2 ± 1.7 * 84.9 ± 1.2 *^    
Word-Color PWS+S 26 49.2 ± 11.1 55.0 ± 9.6 55.6 ± 10.2 53.3 ± 1.8 Group 0.42 
(counts) PWS 27 53.1 ± 5.9 56.7 ± 7.4 59.1 ± 7.6 56.3 ± 1.7 Time < 0.001 
 PLA 27 54.1 ± 11.5 55.5 ± 11.5 58.5 ± 12.6 56.0 ± 1.7 G x T 0.17 
 Mean ± SE  52.1 ± 1.0 55.7 ± 1.0 * 57.7 ± 1.1 *^    
Values are means ± standard deviations. Word, Color, and Word-Color counts were analyzed by MANOVA. MANOVA 
analysis revealed overall Wilks' Lambda group (p=0.83), time (p<0.001), and group x time (p=0.17). Greenhouse-Geisser 
time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. a denotes a significant 
difference from PWS+S. b denotes a significant difference from PWS. c denotes a significant difference from PLA. * 
represents p<0.05 difference from baseline. ^ represents p<0.05 difference from wk 4. 
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Table 17. Study 2 - Readiness to Perform Visual Analogue Scale       
Variable Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
I slept well last night PWS+S 26 3.21 ± 1.09 b 3.26 ± 1.11 3.59 ± 0.91 3.36 ± 0.14 Group 0.25 
 PWS 27 3.77 ± 0.93 
a 3.75 ± 0.89 3.52 ± 1.17 3.68 ± 0.13 Time 0.83 
 PLA 27 3.46 ± 0.90 3.43 ± 0.92 3.53 ± 0.90 3.47 ± 0.13 G x T 0.34 
 Mean ± SE  3.48 ± 0.11 3.48 ± 0.11 3.55 ± 0.11    
I am looking forward to today's workout PWS+S 26 3.73 ± 0.66 3.92 ± 0.68 3.93 ± 0.82 3.86 ± 0.10 Group 0.94 
 PWS 27 3.85 ± 0.90 4.01 ± 0.68 3.77 ± 0.86 3.88 ± 0.10 Time 0.21 
 PLA 27 3.93 ± 0.64 3.92 ± 0.61 3.63 ± 0.84 3.83 ± 0.10 G x T 0.35 
 Mean ± SE   3.84 ± 0.08 3.95 ± 0.07 3.78 ± 0.09    
I am optimistic about my future performance PWS+S 26 4.21 ± 0.75 4.30 ± 0.67 3.88 ± 0.99 4.13 ± 0.10 Group 0.25 
 PWS 27 4.50 ± 0.63 4.42 ± 0.63 4.05 ± 0.66 4.32 ± 0.10 Time < 0.001 
 PLA 27 4.39 ± 0.49 4.16 ± 0.66 3.71 ± 0.95 4.09 ± 0.10 G x T 0.51 
 Mean ± SE  4.37 ± 0.07 4.30 ± 0.07 3.88 ± 0.09 *^    
I feel vigorous and energetic PWS+S 26 3.21 ± 0.80 3.00 ± 0.93 b 3.38 ± 0.85 3.20 ± 0.12 Group 0.26 
 PWS 27 3.46 ± 0.94 3.46 ± 0.84 
a 3.55 ± 0.73 3.49 ± 0.12 Time 0.17 
 PLA 27 3.56 ± 0.71 3.24 ± 0.75 3.21 ± 0.93 3.34 ± 0.12 G x T 0.17 
 Mean ± SE   3.41 ± 0.09 3.23 ± 0.09 3.38 ± 0.09    
My appetite is great PWS+S 26 4.05 ± 0.92 3.96 ± 1.03 3.73 ± 1.11 3.91 ± 0.13 c Group 0.13 
 PWS 27 4.03 ± 0.81 
c 4.03 ± 0.88 4.03 ± 0.79 4.04 ± 0.13 Time 0.11 
 PLA 27 4.48 ± 0.64 
b 4.25 ± 0.81 4.17 ± 0.79 4.30 ± 0.13 a G x T 0.62 
 Mean ± SE  4.19 ± 0.09 4.09 ± 0.10 3.97 ± 0.10    
I have little muscle soreness PWS+S 26 3.52 ± 1.17 3.52 ± 1.17 3.73 ± 1.11 3.59 ± 0.14 Group 0.66 
 PWS 27 3.56 ± 1.15 3.67 ± 1.11 3.52 ± 1.00 3.58 ± 0.13 Time 0.92 
 PLA 27 3.84 ± 0.73 3.84 ± 0.99 3.58 ± 1.04 3.74 ± 0.13 G x T 0.68 
 Mean ± SE  3.64 ± 0.11 3.67 ± 0.12 3.61 ± 0.11    
Values are means ± standard deviations. Six questions were analyzed by MANOVA. MANOVA analysis revealed overall Wilks' Lambda group (p=0.27), time 
(p<0.001), and group x time (p=0.66). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. a denotes a 
significant difference from PWS+S. b denotes a significant difference from PWS. c denotes a significant difference from PLA. * represents p<0.05 difference from 
baseline. ^ represents p<0.05 difference from wk 4. 
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Color test among groups over 8-wk following supplementation and there will be 
significant differences of RTP-VAS among groups over 8-wk following supplementation. 
Exercise Performance 
 All strength testing outcomes are presented in Table 18. For bench press 1RM we 
observed significant increases in strength at week 4 for the PWS (8.17 kg; 95% CI 1.88, 
14.47) and PWS+S (6.95 kg; 95% CI 0.62, 13.28), but not for the PLA (5.45 kg, 95% CI 
-0.82, 11.73). By week 8 all groups demonstrated a significant increase in 1RM-BP: PLA 
(7.18 kg, 95% CI 1.01, 13.36), PWS (14.36, 95% CI 8.13, 20.59) and PWS+S (13.84 kg, 
95% CI 7.64, 20.04). No between groups differences were noted at week 4 or week 8 (Fig. 
11a). 
A similar pattern for change in 1RM-LP strength improvement at week 4 was 
observed within the PWS (61.84 kg, 95% CI 24.96, 98.72) and PWS+S (44.89 kg, 95% 
CI 8.31, 81.47) groups, but not for PLA (36.50, 95% CI, -0.21, 73.2). Similarly, by week 
8, all groups increased their 1RM-LP as follows: PLA (43.28 kg, 95% CI 4.16, 82.41), 
PWS (79.23 kg, 95% CI 39.12, 118.54), and PWS+S (89.54 kg, 95% CI 50.55, 128.53). 
No between groups differences were noted at week 4 or week 8 (Fig. 11b). The results 
from the bench and leg press test analysis provides supporting evidence which rejected 
the null hypothesis of hypothesis 17 and 18 which stated that there will be significant 
differences of upper body strength with bench press test among groups over 8-wk 
following supplementation and there will be significant differences of lower body strength 
with leg press test among groups over 8-wk following supplementation. 
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Table 18. Study 2 - Strength Performance Characteristics 
      
Variable  Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
Bench Press 
(kg) 
PWS+S 26 102.0 ± 16.3 106.2 ± 16.7 108.6 ± 17.1 105.6 ± 4.0 Group 0.56 
 PWS 27 96.7 ± 23.1 99.2 ± 21.3 102.7 ± 21.7 99.5 ± 3.9 Time < 0.001 
 PLA 27 100.6 ± 20.8 102.9 ± 24.7 104.0 ± 23.3 102.5 ± 3.9 G x T 0.33 
 Mean ± SE  99.8 ± 2.2 102.8 ± 2.3 * 105.1 ± 2.3 *^    
Leg Press (kg) PWS+S 26 454.2 ± 79.4 474.4 ± 92.1 494.9 ± 100.9 474.5 ± 21.2 Group 0.67 
 PWS 27 436.6 ± 96.6 466.0 ± 101.9 474.0 ± 96.3 458.9 ± 20.8 Time < 0.001 
 PLA 27 472.8 ± 149.8 490.3 ± 134.2 491.1 ± 131.0 484.7 ± 20.8 G x T 0.28 
 Mean ± SE  454.5 ± 12.6 476.9 ± 12.4 * 486.7 ± 12.3 *^    
Values are means ± standard deviations. Strength (Bench and Leg Press) were analyzed by MANOVA. MANOVA analysis 
revealed overall Wilks' Lambda group (p=0.58), time (p<0.001), and group x time (p=0.29). Greenhouse-Geisser time and 
group x time interaction p-levels are reported with univariate group p-levels. a denotes a significant difference from PWS+S. b 
denotes a significant difference from PWS. c denotes a significant difference from PLA. * represents p<0.05 difference from 
baseline. ^ represents p<0.05 difference from wk 4. 
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Figure 11a. Study 2 – Change in 1RM Bench Press. Data are mean change and 95% CI. 
 
 
Figure 11b. Study 2 – Change in 1RM Leg Press. Data are mean change and 95% CI. 
(a) Change in 1RM Bench Press 
(b) Change in 1RM Leg Press 
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Lastly, as it pertains to performance, we did observe a significant increase in WAT 
peak power for PWS+S and PLA at week 4; yet no significant differences were otherwise 
noted at week 8 or other WAT parameters (Table 19). The results from the WAT analysis 
provides supporting evidence which rejected the null hypothesis of hypothesis 19 which 
stated that there will be significant differences of anaerobic capacity with WAT among 
groups over 8 weeks following supplementation. 
Hematologic Characteristics 
While we did observe several significant changes in hematological characteristics, 
these changes were random and occurred within all treatment groups, inclusive of the PLA 
(Table 20). Significant changes in blood chemistry are presented as follows. We observed 
significant time changes in BUN at week 8 for the PWS+S (p < 0.01) and PWS groups (p 
< 0.001), but no significant changes for the PLA group (p = 0.21); however, no between 
group significance was otherwise noted. Creatinine was significantly decreased at week 
four for the PLA (p < 0.01), PWS (p < 0.01) and PWS+S (p = 0.01) groups at week 4 and 
PLA group at week 8 (p < 0.01). There was no significant difference of creatinine between 
groups (p = 0.27), and post-hoc analyses showed no significant difference of PWS (p = 
0.24) but significant difference of PWS+S (p = 0.25) vs. PLA. The BUN/Creatinine ratio 
was significantly elevated at week 4 in the PLA, PWS and PWS+S groups at week 4 and 
week 8 (all, p < 0.001). There was no significant difference for BUN:CRE (p = 0.20) 
between groups. 
Significant changes in glucose were noted at week 4 for the PLA (p < 0.01), PWS 
(p = 0.91) and PWS+S (p = 0.78) groups and again at week 8 for the PLA (p < 0.01), PWS 
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Table 19. Study 2 - Wingate Anaerobic Capacity 
      
Variable  Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
Peak Power (Watt) PWS+S 26 1445 ± 324 1605 ± 444 1544 ± 403 1532 ± 68 Group 0.91 
 PWS 27 1502 ± 384 1602 ± 354 1603 ± 466 1569 ± 67 Time < 0.01 
 PLA 27 1472 ± 485 1630 ± 475 1507 ± 385 1536 ± 67 G x T 0.83 
 Mean ± SE  1473 ± 45 1612 ± 47 * 1551 ± 46    
Mean Power (Watt) PWS+S 26 630 ± 114 656 ± 134 612 ± 145 633 ± 20 Group 0.95 
 PWS 27 630 ± 72 643 ± 66 638 ± 69 637 ± 19 Time 0.23 
 PLA 27 647 ± 146 640 ± 133 636 ± 127 641 ± 19 G x T 0.40 
 Mean ± SE  636 ± 12 646 ± 12 629 ± 13    
Peak Power (Watt/kg) PWS+S 26 18.3 ± 3.6 20.2 ± 5.3 19.4 ± 4.8 19.3 ± 0.7 Group 0.90 
 PWS 27 18.6 ± 4.7 19.8 ± 4.6 19.8 ± 5.8 19.4 ± 0.7 Time 0.01 
 PLA 27 18.3 ± 5.6 20.2 ± 5.4 18.4 ± 4.0 19.0 ± 0.7 G x T 0.80 
 Mean ± SE  18.4 ± 0.5 20.1 ± 0.5 * 19.2 ± 0.5    
Mean Power (Watt/kg) PWS+S 26 8.0 ± 1.1 8.2 ± 1.4 8.0 ± 1.2 8.1 ± 0.2 Group 0.73 
 PWS 27 7.8 ± 1.2 8.0 ± 1.1 7.9 ± 1.0 7.9 ± 0.2 Time 0.18 
 PLA 27 8.0 ± 1.1 7.9 ± 1.0 7.7 ± 0.9 7.8 ± 0.2 G x T 0.33 
 Mean ± SE  7.9 ± 0.1 8.0 ± 0.1 7.9 ± 0.1    
Total Work (Joule) PWS+S 26 18923 ± 3431 19680 ± 4025 19213 ± 3110 19272 ± 629 Group 0.98 
 PWS 27 18927 ± 2166 19319 ± 2003 19156 ± 2095 19134 ± 618 Time 0.17 
 PLA 27 19394 ± 4377 19217 ± 4019 19109 ± 3826 19240 ± 618 G x T 0.29 
 Mean ± SE  19081 ± 385 19405 ± 388 19159 ± 345    
Values are means ± standard deviations. Anaerobic performance (Peak Power, Mean Power, and Total Work) was analyzed by MANOVA. 
MANOVA analysis revealed overall Wilks' Lambda group (p=0.88), time (p=0.02), and group x time (p=0.85). Greenhouse-Geisser time and group x 
time (G x T) interaction p-levels are reported with univariate group p-levels. * represents p<0.05 difference from baseline. 
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(p = 0.01) and PWS+S (p = 0.05) groups. Finally, our assessment of hematology 
examining changes from “normal” to exceeding clinical limits showed no between group 
differences and, similar to individual markers of hepatorenal and muscle enzyme function, 
the changes associated with normal clinical status were randomly distributed amongst all 
treatment groups (Table 21). The results from the blood chemistry analysis provides 
supporting evidence which accepted the null hypothesis 20 through 23 which stated that 
there will be no significant differences of blood metabolic markers; cholesterol, HDL-C, 
LDL-C, glucose, LDH and CK, CRE and BUN, ALP, ALT, and AST, among groups over 
8-wk following supplementation.  
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Table 20. Study 2 - Hematological Characteristics 
 
      
Variable  Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
ALP PWS+S 26 76.4 ± 22.8 68.1 ± 17.3 74.4 ± 19.6 73.0 ± 3.5 Group 0.24 
(U/L) PWS 27 87.2 ± 24.7 72.3 ± 19.0 78.4 ± 24.9 79.3 ± 3.4 Time < 0.001 
 PLA 27 76.8 ± 15.1 66.4 ± 12.9 71.2 ± 13.4 71.5 ± 3.4 G x T 0.24 
 Mean ± SE  80.1 ± 2.3 68.9 ± 1.8 * 74.7 ± 2.2 *^       
ALT PWS+S 26 26.6 ± 23.0 28.6 ± 20.8 26.0 ± 12.2 27.1 ± 2.6 Group 0.74 
(U/L) PWS 27 25.1 ± 10.1 26.9 ± 16.0 30.9 ± 17.9 27.6 ± 2.5 Time 0.73 
 PLA 27 25.3 ± 10.0 25.0 ± 22.4 24.6 ± 13.0 25.0 ± 2.5 G x T 0.55 
 Mean ± SE  25.7 ± 1.7 26.8 ± 2.2 27.2 ± 1.6       
AST PWS+S 26 28.4 ± 15.1 28.4 ± 10.3 27.3 ± 8.5 28.0 ± 2.1 Group 0.47 
(U/L) PWS 27 28.8 ± 9.7 31.6 ± 26.1 33.1 ± 19.7 31.1 ± 2.0 Time 0.96 
 PLA 27 29.1 ± 11.0 27.6 ± 17.7 27.1 ± 9.8 27.9 ± 2.0 G x T 0.75 
 Mean ± SE  28.7 ± 1.3 29.2 ± 2.1 29.1 ± 1.5    
BUN PWS+S 26 13.6 ± 4.9 12.6 ± 6.6 16.5 ± 5.0 14.5 ± 0.7 Group 0.62 
(mg/dl) PWS 27 12.0 ± 4.0 c 12.3 ± 5.8 16.1 ± 5.3 13.5 ± 0.7 Time < 0.001 
 PLA 27 14.9 ± 4.9 b 12.3 ± 6.7 16.2 ± 6.8 14.2 ± 0.7 G x T 0.54 
 Mean ± SE  13.5 ± 0.5 12.4 ± 0.7 16.3 ± 0.6 *^       
Creatinine PWS+S 26 1.13 ± 0.51 0.82 ± 0.43 1.05 ± 0.28 c 1.01 ± 0.04 Group 0.27 
(mg/dl) PWS 27 1.08 ± 0.41 0.75 ± 0.38 0.95 ± 0.31 0.93 ± 0.04 Time < 0.001 
 PLA 27 1.15 ± 0.44 0.72 ± 0.47 0.85 ± 0.36 a 0.90 ± 0.04 G x T 0.78 
 Mean ± SE  1.1 ± 0.0 0.7 ± 0.0 * 0.9 ± 0.0 *^       
BUN:Creatinine PWS+S 26 15.3 ± 10.9 20.9 ± 15.1 17.9 ± 12.6 18.0 ± 1.8 Group 0.20 
 PWS 27 12.7 ± 6.8 22.7 ± 17.3 20.4 ± 15.0 18.6 ± 1.8 Time 0.002 
 PLA 27 15.7 ± 9.6 24.7 ± 19.1 26.5 ± 23.4 22.3 ± 1.8 G x T 0.62 
 Mean ± SE  14.6 ± 1.0 22.8 ± 1.9 21.6 ± 1.9 *      
Glucose PWS+S 26 90.7 ± 8.2 90.1 ± 5.0 c 95.4 ± 7.9 92.1 ± 1.2 Group 0.90 
(mg/dl) PWS 27 89.4 ± 7.1 89.7 ± 8.9 c 95.1 ± 9.2 91.4 ± 1.2 Time < 0.001 
 PLA 27 86.6 ± 7.0 93.7 ± 12.8 a,b 93.8 ± 13.0 91.3 ± 1.2 G x T 0.09 
 Mean ± SE  88.9 ± 0.8 91.2 ± 1.0 94.8 ± 1.1 *^    
Values are means ± standard deviations. All variables were analyzed by MANOVA. MANOVA analysis revealed overall Wilks' Lambda group (p=0.47), time 
(p<0.001), and group x time (p=0.67). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. a denotes a 
significant difference from PWS+S. b denotes a significant difference from PWS. c denotes a significant difference from PLA. * represents p<0.05 difference from 
baseline. ^ represents p<0.05 difference from wk 4. 
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Table 20. Continued 
 
      
Variable  Group N 
Time (wk) 
Mean ± SE 
 
p-level 
0 4 8   
Cholesterol PWS+S 26 174.5 ± 42.8 171.9 ± 40.9 165.9 ± 36.1 170.8 ± 6.5 Group 0.34 
(mg/dl) PWS 27 164.1 ± 31.3 158.1 ± 26.0 163.3 ± 32.8 161.8 ± 6.4 Time 0.16 
 PLA 27 159.5 ± 31.6 156.9 ± 34.3 156.1 ± 41.7 157.5 ± 6.4 G x T 0.43 
 Mean ± SE  166.1 ± 3.9 162.3 ± 3.8 161.7 ± 4.1    
HDL-C PWS+S 26 53.5 ± 16.2 52.7 ± 12.7 49.6 ± 15.0 51.9 ± 2.6 Group 0.99 
(mg/dl) PWS 27 52.7 ± 14.7 50.0 ± 13.9 52.6 ± 14.7 51.8 ± 2.5 Time 0.10 
 PLA 27 53.4 ± 12.6 51.8 ± 13.1 51.3 ± 15.0 52.2 ± 2.5 G x T 0.24 
 Mean ± SE  53.2 ± 1.6 51.5 ± 1.4 51.2 ± 1.6       
CHL:HDL PWS+S 26 3.9 ± 3.7 3.5 ± 1.8 4.1 ± 4.4 3.8 ± 0.3 Group 0.38 
 PWS 27 3.2 ± 0.9 3.3 ± 0.8 3.2 ± 0.7 3.2 ± 0.3 Time 0.35 
 PLA 27 3.1 ± 0.7 3.1 ± 0.8 3.1 ± 0.7 3.1 ± 0.3 G x T 0.21 
 Mean ± SE  3.4 ± 0.3 3.3 ± 0.1 3.5 ± 0.2       
LDL-C PWS+S 26 121.0 ± 35.2 119.2 ± 42.3 116.2 ± 42.2 118.8 ± 6.4 Group 0.32 
(mg/dl) PWS 27 111.4 ± 29.8 108.0 ± 23.4 110.6 ± 27.9 110.0 ± 6.3 Time 0.43 
 PLA 27 106.0 ± 29.6 105.0 ± 31.4 104.7 ± 35.1 105.2 ± 6.3 G x T 0.81 
 Mean ± SE  112.8 ± 3.9 110.7 ± 3.7 110.5 ± 3.9       
Triglyceride PWS+S 26 81.6 ± 36.6 73.9 ± 22.9 b 80.4 ± 41.9 78.6 ± 5.2 Group 0.11 
(mg/dl) PWS 27 92.8 ± 43.3 98.5 ± 37.8 a 86.5 ± 37.6 92.6 ± 5.1 Time 0.89 
 PLA 27 74.2 ± 33.8 81.9 ± 31.5 83.6 ± 30.7 79.9 ± 5.1 G x T 0.31 
 Mean ± SE  82.9 ± 4.2 84.8 ± 3.5 83.5 ± 4.1     
CK PWS+S 26 504.6 ± 1075.5 382.6 ± 375.4 349.8 ± 316.2 412.3 ± 83.0 Group 0.34 
(U/L) PWS 27 395.6 ± 391.1 504.4 ± 1301.4 443.8 ± 607.8 447.9 ± 81.4 Time 0.79 
 PLA 27 337.2 ± 255.7 263.1 ± 214.4 256.9 ± 242.7 285.7 ± 81.4 G x T 0.85 
 Mean ± SE  412.4 ± 74.9 383.4 ± 88.9 350.2 ± 47.0       
LDH PWS+S 26 158.8 ± 32.1 152.5 ± 24.3 160.4 ± 23.6 157.2 ± 4.9 Group 0.90 
(U/L) PWS 27 157.7 ± 24.2 160.7 ± 37.6 162.8 ± 24.3 160.4 ± 4.8 Time 0.18 
 PLA 27 164.2 ± 36.2 153.5 ± 33.9 159.4 ± 29.5 159.0 ± 4.8 G x T 0.43 
 Mean ± SE  160.2 ± 3.4 155.5 ± 3.6 160.9 ± 2.9       
Values are means ± standard deviations. All variables were analyzed by MANOVA. MANOVA analysis revealed overall Wilks' Lambda group (p=0.47), time 
(p<0.001), and group x time (p=0.67). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. a denotes a 
significant difference from PWS+S. b denotes a significant difference from PWS. c denotes a significant difference from PLA. * represents p<0.05 difference from 
baseline. ^ represents p<0.05 difference from wk 4. 
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Table 21. Study 2 - Prevalence of Blood Chemistry Changes Exceeding Normal 
Clinical Bounds 
      Placebo PWS+S PWS Significance 
L
ip
id
s 
&
 G
lu
co
se
 
Cholesterol No Change 23 25 24 0.42 
 Normal Baseline, Exceed at 4-wk 2 1 0  
 Normal Baseline, Exceed at 8-wk 0 0 1  
  Normal 4-wk, Exceed 8-wk 2 0 2   
HDL-C No Change 25 26 21 0.10 
 Normal Baseline, Exceed at 4-wk 1 0 1  
 Normal Baseline, Exceed at 8-wk 1 0 1  
  Normal 4-wk, Exceed 8-wk 0 0 4   
LDL-C No Change 15 17 15 0.49 
 Normal Baseline, Exceed at 4-wk 11 9 9  
 Normal Baseline, Exceed at 8-wk 1 0 1  
  Normal 4-wk, Exceed 8-wk 0 0 2   
Triglycerides No Change 27 25 27 0.35 
 Normal Baseline, Exceed at 4-wk 0 1 0  
 Normal Baseline, Exceed at 8-wk 0 0 0  
  Normal 4-wk, Exceed 8-wk 0 1 0   
Glucose No Change 21 24 23 0.49 
 Normal Baseline, Exceed at 4-wk 2 0 0  
 Normal Baseline, Exceed at 8-wk 1 0 1  
  Normal 4-wk, Exceed 8-wk 3 2 3   
Muscle 
LDH No Change 20 18 18 0.74 
 Normal Baseline, Exceed at 4-wk 1 0 2  
 Normal Baseline, Exceed at 8-wk 2 3 1  
  Normal 4-wk, Exceed 8-wk 4 5 6   
Creatine No Change 19 21 22 0.42 
Kinase Normal Baseline, Exceed at 4-wk 1 0 0  
 Normal Baseline, Exceed at 8-wk 0 2 1  
  Normal 4-wk, Exceed 8-wk 7 3 4   
Data are frequency of occurrence. Significance is by chi-square analysis. 
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Table 21. Continued 
      Placebo PWS+S PWS Significance 
K
id
n
ey
 
Creatinine No Change 23 23 25 0.72 
 Normal Baseline, Exceed at 4-wk 2 1 0  
 Normal Baseline, Exceed at 8-wk 0 0 0  
  Normal 4-wk, Exceed 8-wk 2 2 2   
BUN No Change 17 19 18 0.41 
 Normal Baseline, Exceed at 4-wk 3 1 2  
 Normal Baseline, Exceed at 8-wk 0 2 0  
  Normal 4-wk, Exceed 8-wk 7 4 7   
L
iv
er
 
ALP No Change 25 25 23 0.28 
 Normal Baseline, Exceed at 4-wk 1 0 0  
 Normal Baseline, Exceed at 8-wk 0 0 0  
  Normal 4-wk, Exceed 8-wk 1 1 4   
ALT No Change 24 22 22 0.72 
 Normal Baseline, Exceed at 4-wk 1 0 0  
 Normal Baseline, Exceed at 8-wk 1 1 2  
  Normal 4-wk, Exceed 8-wk 1 3 3   
AST No Change 23 21 21 0.84 
 Normal Baseline, Exceed at 4-wk 1 1 1  
 Normal Baseline, Exceed at 8-wk 0 2 1  
 Normal 4-wk, Exceed 8-wk 3 2 4  
Data are frequency of occurrence. Significance is by chi-square analysis. 
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
Study 1 
The primary aim of Study 1 was to examine the acute effects of ingesting a dietary 
pre-workout supplement with and without synephrine. Safety was assessed via 
hematologic, and blood pressure and heart rate changes, and readiness was examined via 
the Stroop Test and Readiness to Perform questionnaires. When examined acutely, 
participants ingesting PWS and PWS+S demonstrated a consistent pattern regarding 
improving readiness to perform and cognitive function regardless of the presence of 
synephrine. While we did observe minor, yet significant changes in some indices of 
hepatorenal and metabolic function, it should be noted that the values remained within 
normal, clinical and expected ranges, demonstrated an irregular pattern, and were 
observed changes within all treatment groups, inclusive of PLA. Lastly, we did not 
observe any significant changes for exercise performance. Thus, we conclude that acute 
ingestion of the PWS examined in this study is safe and efficacious regarding readiness to 
performance and that the inclusion of synephrine to the PWS is unnecessary to achieve 
additional treatment effects. 
Numerous studies have evaluated the effects of ingesting a PWS containing a 
variety of nutrients on readiness to perform, cognitive function, and exercise performance. 
Unfortunately, it is difficult to compare our results to those of others given the difference 
in formulations used in respective studies. For example, Little et al. [178] showed that the 
acute administration of combining creatine and α-ketoglutarate had a greater impact on 
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upper body muscle endurance and peak power output during repeated Wingate test than 
creatine alone. Similar studies have reported a greater time to exhaustion at 70% of VO2 
max, as well as a higher level of perceived focus, energy and less fatigue with PWS 
ingestion versus a placebo [10].  For cognitive function, the acute ingestion of herbal 
supplement, containing guarana, Ginkgo biloba, and elderberry, showed better 
performance of “vigilance”, “focus ability”, and “effectiveness at work” at 30 min and 
120 min of following lunch with no adverse hemodynamic consequences [179].  
Zak and colleagues [15] examined the acute effects of a multi-ingredient arginine-
based supplement, including 3 g of arginine, 0.3 g of grape seed extract, and 0.3 g of 
polyethylene glycerol, on neuromuscular, ventilator, and metabolic fatigue thresholds 
during cycle ergometer and found the onset of neuromuscular fatigue delay and the 
ventilator threshold (VT) improvement in untrained individuals. Further, Gonzalez et al. 
[54] observed that an acute ingestion of a pre-workout supplement containing caffeine, β-
alanine, and creatine significantly increased the number of repetitions performed at 80% 
of 1RM, as well as peak and mean power of bench press.  
Despite the varied formulations used in the aforementioned studies, the primary 
difference in our current investigation is the inclusion or exclusion of synephrine. As such, 
few studies have been performed using synephrine in combination with other ingredients.  
Haller and associates [180] reported that the acute ingestion of caffeine (304 mg) and 
synephrine (21 mg) had no significant adverse effects although they noted a modest, yet 
normal increase in diastolic blood pressure accompanying supplementation.  Ratamess et 
al. [181] investigated the effects of ingesting either synephrine alone (100 mg) or in 
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combination with caffeine (100 mg) for 3-d on resistance training performance indices. 
The researchers reported that both treatment groups increased their number of lifting 
repetitions and lifting volume vs. control and placebo groups. Further, mean power and 
lifting velocity was also reported to be higher for the caffeine and synephrine group. 
Consistent with our study, these authors reported no adverse effects in response to 
supplementation [181]. Finally, Gutierrez-Hellin [182] examined the acute effects of 
consumption of synephrine (3 mg/kg) on sprint performance in experienced sprinters 
undertaking series of performance sprint and power related exercise testing. Ingestion of 
synephrine did not increase exercise performance, nor did it cause any side effects. Similar 
to our findings, Stohs et al. [172] reported no significant changes in heart rate or blood 
pressure or self-reported symptomology accompanying the ingestion of 50 mg of 
synephrine with 100 to 1,000 mg of heparidin and 600 mg of naringin.   
In the present study, we observed a significant increase in a VAS determined 
feelings of “optimism about future performance” and “vigorous and energetic feeling” 
using both treatments (i.e. with and without synephrine). Additionally, we found evidence 
that ingestion of the PWS prior to exercise increased some measures of cognitive function. 
However, the addition of synephrine to the PWS supplements used in our study did not 
provide additive benefit to perceptions about readiness to perform or feelings of 
energy/vigor. Our results are in agreement with Hoffman et al. [183] who observed a 
significantly greater feeling of energy and focus compared to placebo after ingesting a 
supplement containing various herbal and amino acids and are contrary to Gonzales et al. 
[54] who reported no significant difference in VAS determined feeling of energy when 
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ingesting a supplement containing caffeine, creatine, β-alanine. The improved perception 
about readiness to perform and cognitive function observed, however, did not translate 
into significant improvements in muscular endurance or anaerobic capacity. Thus, while 
perceptions about readiness to perform and cognitive function may have been improved, 
this did not result in greater exercise performance.   
A strength of Study 1 is that we performed a well-controlled clinical trial 
examining the comprehensive acute effects of ingesting a PWS with and without 
synephrine on indices of readiness, cognition, and exercise performance in the same 
individuals. Additionally, we conducted a detailed analysis of markers of safety and 
observed no significant alterations in respective blood pressure, heart rate and hematologic 
variables with either supplement form.  A weakness of this study is that these results can 
only be attributed to the PWS studied and additional research is needed to determine the 
acute and chronic effects of ingesting other PWS on cognitive and exercise performance 
capacity as well as safety.   
Study 2 
The primary aim of Study 2 was to examine the chronic effect of PWS with and 
without synephrine for 8 weeks on training adaptation in resistance trained athletes. In this 
study, we focused on the long term exercise performance and cognitive function while 
also monitoring for safety. Accordingly, we did observe several significant improvements 
in strength and cognitive function performance favoring a PWS and that synephrine was 
not necessary to achieve these effects. Accompanying these findings was a lack of 
significant effects on blood pressure, heart rate or hematological changes over the 8-wk 
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for either treatment group. While a few indices of hepatorenal and metabolic function did 
show significant changes, inclusive of the PLA group, it should be noted that the values 
did not demonstrate a consistent pattern for any treatment group. This becomes readily 
apparent when examining Table 21, which reports on those individuals exceeding clinical 
limits at specific time points during the study period. As it pertains to body composition, 
we did not observe any significant changes in DXA determined aspects of anthropometry. 
Our results suggest that a PWS with and without synephrine is safe and efficacious 
regarding readiness and exercise performance and that the inclusion of synephrine is 
unnecessary to achieve the observed treatment effects, though it does appear that 
synephrine does offer better overall improvements in cognition when taken acutely. 
While much attention has been given to single nutrition ergogenic aids, fewer 
studies have examined the effects of multi-ingredient supplements and their potential 
effects on physical performance. Fewer still have examined additional factors such as 
readiness to perform and cognitive function. A comparison between our study and earlier 
work is difficult as each pre-workout formula can differ with regard to ingredients. While 
earlier studies generally focused on variations of creatine, amino acids, β-alanine and 
various admixtures of ingredients, newer investigations have begun to examine nitrates as 
an adjunct to re-ingestion formula. For example, in 2009, Hoffman et al. [183] examined 
the effects of ingesting a pre-exercise energy drink containing β-alanine and caffeine as 
the primary ingredients of a multi-ingredient formula and found no significant differences 
in measurements of anaerobic power despite participants reporting higher subjective levels 
feeling energized and focused. These latter effects were complimented by greater number 
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of targets struck during a Makato Test. In similar study ingesting a multi-ingredient 
supplement containing 400 mg of phosphatidylserine and 100 mg of caffeine, 2-wk 
supplement intake showed to attenuate post-exercise mood scores and perception of 
fatigue, while not to affect cognitive function or reaction time [184]. 
 Similar reports by others have observed a greater time to exhaustion at 70% of 
VO2 max, as well as a higher level of perceived focus, energy and less fatigue versus a 
placebo [10]. In the same year, Smith et al. [11] reported on the effects of ingesting a pre-
workout supplement containing caffeine, creatine, and various amino acids during 3-wk 
of high-intensity interval training, which resulted in an increase in VO2 max, overall 
training volume, lean body mass increase and a decrease in percent body fat versus those 
taking a placebo. Shortly after this time period, nitrates, primarily from beetroot juice, 
were introduced as a viable pre-workout ingestion strategy and in 2013, Lowery et al. [13] 
demonstrated that a multi-ingredient supplement containing branched chain amino acids, 
creatine monohydrate, β-alanine, quercetin, coenzymated B-vitamins, alanyl-glutamine 
and nitrate from pomegranate and beetroot extracts increased upper body strength, muscle 
hypertrophy and muscle thickness. Our study therefore adds to the literature of using 
nitrate, in combination with other ingredients, as a pre-workout strategy. Overall, our 
study showed no adverse effects of blood pressure, heart rate or hematological 
characteristics typically associated with hepatorenal or muscle enzymes alterations. This 
is important as recent criticisms suggest that the evidence supporting multi-ingredient 
formulas do improve performance, but are matched by inclusive and incomplete reports   
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regarding safety and side effects. Thus, of our report strengthens and enhances the 
literature via its thorough reporting of possible side effects. 
A major strength of Study 2 is that it elaborates on the findings of Study 1 lasting 
just a few hours. The results of the combined studies demonstrate no adverse 
hematological or blood pressure, heart rate effects following the acute or chronic ingestion 
of a pre-workout supplement. Further PWS and PWS+S increased readiness and cognitive 
function acutely and chronically based on the results from Stroop testing. While we did 
observe significant strength increase, we did not observe change in body composition.  
Another strength is that we compared a multi-ingredient formula with and without 
synephrine, which also has had concerns raised regarding safety. Similar to our findings, 
Kaats et al. [167] reported no significant changes in hemodynamic or hematological safety 
indices accompanying 49 mg/d or 98 mg/d of synephrine ingestion for 60-d. These 
findings are cumulatively supported by a review of Stohs et al. [185]. An interesting 
finding of Study 2 is that synephrine does not appear to add to the overall effectiveness of 
the formula we investigated when taken chronically. 
Summary and Conclusion 
In summary, results from Study 1 assessing the acute effects of PWS 
supplementation with and without synephrine suggest that acute ingestion of PWS can 
improve cognitive function and perceptions of readiness to perform but has no impact on 
bench press, leg press, or anaerobic sprint capacity. Adding synephrine to the PWS did 
not significantly affect resting energy expenditure or provide additive effects to cognitive 
or exercise performance. Results also suggest that acute ingestion of the PWS’s did not 
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significantly affect hematological or blood pressure, heart rate variables following the 
ingestion of a pre-workout supplement for a short-term; 60 min to 120 min.  
During Study 1, we observed a significant increase in a RTP assessment 
demonstrating increased feeling of “optimism about future performance” and “vigorous 
and energetic feeling” using both treatments (i.e. with and without synephrine). Our results, 
however, did not persist through the chronic ingestion for 8-wk of our trial. Interestingly, 
our use of the Stroop Word-Color initially demonstrated quite a different effect whereby; 
both treatment groups exhibited a significant increase in respective measurement indices 
during the acute study, while the effect observed during chronic study of our trial 
demonstrated a nearly two-fold higher affect for the PWS vs. PLA or PWS+S conditions. 
Thus, we suggest that the pre-workout supplement examined here is safe when 
taken both acutely and chronically. Also, our findings support PWS beneficial effects to 
physical and cognitive performance while it is equally effective whether or not it contains 
synephrine.  
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